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 ABSTRACT 
The insulin/insulin-like growth factor signaling axis is a complex system that is 
involved in the regulation of metabolism and body growth. It includes three related peptide 
hormones: insulin and two insulin-like growth factors (IGF-1 and IGF-2), and their 
receptors: two isoforms of insulin receptor (IR-A and IR-B), and IGF-1 receptor (IGF-1R). 
Whereas insulin is involved predominantly in regulation of the metabolism, IGFs 
participate mainly in the regulation of cell growth, proliferation and differentiation. Due to 
the similarities in the structures of both the hormones and the receptors, all the hormones 
can bind and activate all the receptors, although with different potencies. At which point 
and how are the „metabolic“ and „mitogenic“ functional outcomes of the system 
diversified, as well as the structural determinants responsible for the different affinities of 
the hormones to the individual receptors, is still not completely understood. Deregulation 
of the insulin/IGF system can result in many types of pathological states, mainly diabetes 
mellitus and cancer. Therefore, to deeply understand the functioning of the insulin/IGF 
system to the structural details is crucial for development of analogs with desirable 
properties, that are of great clinical interest.  
First of all, we developed a suitable methodology for testing the ability of broad 
spectrum of insulin and IGF analogs, that are produced in our laboratory, to activate all the 
three receptors of the insulin/IGF system. This methodology serves to complement our 
well established binding assays. We used this methodology to test several sets of 
insulin/IGF analogs, as well as insulin nonpeptide mimetics.  
In this thesis, we tested binding and activation properties of insulin-IGF-1/IGF-2 
hybrids containing parts derived from the C and D domains of IGFs, that are not present in 
insulin. We tested the properties of IGF-1 and IGF-2 analogs wih mutations in positions 
45, 46 and 49 (IGF-1) and 45 and 48 (IGF-2). We also utilized our methodology for testing 
libraries of specially developed insulin nonpeptide mimetics. 
During routine testing of other sets of compounds, we identified an insulin analog 
with unexpectedly increased affinity and ability to activate IGF-1R ([D-HisB24]-insulin) 
and we designed and synthesized a new set of insulin analogs to explain this behaviour. 
We found an insulin-derived binder and activator of IGF-1R, which is to the best of our 
knowledge one of the strongest ever reported ([D-HisB24, GlyB31, TyrB32]-insulin).  
This analog shows increased ability to bind and activate both isoforms of IR as well.  
We customized methodologies for kinetic characterisation of the binding of the ligands to 
 IR-A and IGF-1R, which revealed that different kinetic behaviours were behind  
the increased affinities of our analog to IGF-1R and IR-A.  
Our data provided new insights into the interaction of insulin, IGF-1 and IGF-2 
with their receptors, which may be useful for further rational engineering of new hormone 
analogs for potential medical applications. 
 ABSTRAKT 
Systém insulinu a insulinu podobných růstových faktorů (IGF) je velmi komplexní 
soustava podílející se na regulaci metabolismu a buněčného a tělesného růstu.  Součástí 
tohoto systému jsou tři strukturně příbuzné peptidové hormony: insulin a dva insulinu 
podobné růstové faktory (IGF-1 a IGF-2) a jejich membránové receptory: dvě isoformy 
insulinového receptoru (IR-A a IR-B) a IGF-1R receptor (IGF-1R). Zatímco insulin se 
podílí převážně na regulaci metabolismu, IGF-1 a IGF-2 se účastní hlavně regulace 
buněčného růstu, proliferace a diferenciace. Vzhledem ke strukturní podobnosti jak 
hormonů, tak jejich receptorů, mají všechny hormony schopnost vázat se ke všem třem 
receptorům a aktivovat je, i když v různé míře. Jak dochází k odlišení „metabolických“  
a „mitogenních“ buněčných odpovědí po stimulaci receptorů jednotlivými ligandy nebylo 
stále zcela objasněno, stejně jako klíčové strukturní faktory podílející se na rozdílných 
afinitách jednotlivých ligandů k IR-A, IR-B a IGF-1R. Nerovnováha v celém systému vede 
k řadě patologických stavů, z nichž nejvýznamnější jsou diabetes mellitus a rakovina. 
Porozumění celému systému na strukturní úrovni je tedy zásadní pro vývoj analogů  
se žáoucími vlastnostmi, uplatnitelných v klinické praxi. 
V rámci této práce byla nejprve optimalizována metodologie vhodná pro testování 
schopnosti aktivotat všechny tři zmíněné receptory širokého spektra analogů insulinu,  
IGF-1 a IGF-2, vyvíjených v naší laboratoři. Tato metoda doplňuje vazebné testy, které 
jsou v naší laboratoři zavedeny.   
V této práci byly otestovány vazebné a aktivační vlastnosti hybridních analogů 
insulinu a IGF-1/IGF-2, které obsahovaly aminokyselinové sekvence odvozené z C a D 
domén IGF-1 a IGF-2 připojené k molekule insulinu. Dále byly otestovány vlastnosti 
analogů IGF-1 a IGF-2 nesoucích mutace v pozicích 45, 46 a 49 (IGF-1) a 45 a 48 (IGF-2). 
Naší metodologii jsme využili také pro testování aktivačních vlastností knihoven speciálně 
vyvinutích nepeptidových insulinových mimetik. 
V rámci rutinního testování dalších skupin analogů jsme identifikovali insulinový 
analog s neočekávaně zvýšenou afinitou a schopností aktivovat IGF-1R  
([D-HisB24]-insulin). Proto jsme navrhli a připravili novou skupinu insulinových analogů 
s cílem objasnit tyto vlastnosti. Následně byl identifikován analog, který se na IGF-1R 
vázal a aktivoval ho v ještě vyšší míře než analog původní ([D-HisB24, GlyB31,  
TyrB32]-insulin). Podle našich nejlepších znalostí se jedná o jeden z nejsilnějších 
insulinových analogů vůči IGF-1R vůbec. Tento analog vykazoval také zvýšenou afinitu  
 a schopnost aktivovat obě isoformy IR. V další části práce byla charakterizována kinetika 
vazby tohoto analogu, insulinu a IGF-1 vůči IR-A a IGF-1R. Bylo zjištěno, že za zvýšenou 
vazbou našeho analogu vůči IGF-1R a IR-A stojí rozdílné kinetické vlastnosti.  
Naše data poskytují nové poznatky o interakci insulinu, IGF-1 a IGF-2 s jejich 
receptory, které mohou být užitečné pro vývoj nových analogů těchto hormonů 
uplatnitelných v klinické praxi.  
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1 INTRODUCTION 
 
1.1 Insulin/insulin-like growth factor (IGF) system 
The insulin/IGF system is a complex system of three related peptide hormones, 
their membrane receptors and plasmatic binding proteins that together control many 
aspects of cell metabolism as well cell as growth and proliferation. The hormones involved 
are insulin and two insulin-like growth factors (IGF-1 and IGF-2) that trigger their function 
through binding to closely related receptor tyrosine kinases – two isoforms of insulin 
receptor (IR-A and IR-B) and IGF-1 receptor (IGF-1R). The receptor for IGF-2 (IGF-2R, 
also known as the cation-independent mannose-6-phosphate (M6P) receptor) also belongs 
to the insulin/IGF system. It is a distinct type of receptor, which serves to regulate the 
amount of circulating and tissue IGF-2 and it is involved in the sorting of M6P-marked 
lysosomal enzymes. No specific signaling function of IGF-2R has been identified so far  
(1-3).  
There are also six plasmatic IGF binding proteins (IGFBP-1 to 6). These proteins 
bind IGF-1 and IGF-2, but not insulin, and they regulate the concentration of free IGFs in 
plasma (1,2). 
The three hormones have distinct yet overlapping roles in the organism. While 
insulin is involved predominantly in regulation of the metabolism of glucose and lipids in 
muscle, fat and liver, the IGFs participate mainly in regulation of cell growth, proliferation 
and differentiation, both during the fetal development and postnatally. However, it is well 
known that all the hormones can bind and activate all the three receptors (i.e. IR-A, IR-B 
and IGF-1R), although with different binding affinities. This is schematically shown in the 
figure 1 and the binding affinities of the ligands for the individual receptors are shown in 
table 1. Whether the diversification of the “metabolic” versus “mitogenic” outcome arises 
at a level of the specific hormone-receptor interaction or it is rather associated  with a 
different tissue distribution of the hormones and the receptors, is still not completely 
understood. It seems that both mechanisms are involved. 
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Figure 1: Ligands and receptors of the insulin/IGF system and a schematic 
representation of their binding properties. The full lines represent high, dashed lines 
low and spotted lines very low affinity binding. The image was prepared and kindly 
provided by Dr. Lenka Žáková.  
 
 
Table 1: Binding affinities of human insulin, IGF-1 and IGF-2 for IR-A, IR-B and IGF-1R 
determined in our laboratory. Kds are mean values ± SD obtained from at least three 
experiments. Adapted from (4).   
 
 IR-A IR-B IGF-1R 
 
Kd ± SD 
[nM] 
Relative 
affinity ± SD 
[%] 
Kd ± SD 
[nM] 
Relative 
affinity ± SD 
[%] 
Kd ± SD 
[nM] 
Relative 
affinity ± SD 
[%] 
Insulin 
IGF-1 
IGF-2 
0.34 ± 0.08 
31.50 ± 5.63 
2.92 ± 0.24 
100  
1.1 ± 0.5  
8.4 ± 0.6 
0.47 ± 0.10  
223.9 ± 32.9  
35.45 ± 11.22 
100  
0.2 ± 0.1 
1.6 ± 0.9 
292 ± 54 
0.18 ± 0.08 
2.32 ± 1.24  
0.08 ± 0.03 
100 
10.7 ± 5.8 
 
Imbalances in the insulin/IGF system are associated with many patological states as 
type 1 and 2 diabetes mellitus (DM) (5,6), growth disorders as the Laron syndrome (7) or 
acromegaly (8) as well as cancer (5,6). Therefore, to better understand the whole system 
and its function is crucial for the development of new terapeutics.  
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1.1.1 Ligands of the insulin/IGF system 
Insulin and both IGFs are closely related peptides that share high homology in their 
aminoacid sequences as well as tertiary structures, which is described in detail in chapters 
1.2.1 and 1.2.2. The most obvious difference between them is that while insulin is a two 
chain peptide (consisting of so called A chain and B chain), both IGF consist of one chain 
only (9-11).  
 
1.1.1.1 Insulin: role, biosynthesis and in vivo distribution 
Insulin is a hormone that plays a central role in the regulation of human 
metabolism. The best known effect of insulin is the regulation of blood glucose levels. 
Insulin decreases plasma glucose concentration by stimulation of glucose uptake by liver, 
fat and muscle cells, by suppression of hepatic gluconeogenesis and by stimulation of 
glycogen synthesis in liver, adipose tissue and muscle. Insulin also mediates lipid and 
protein metabolism. It decreases the rate of lipolysis in adipose tissue and stimulates 
synthesis of lipids, including fatty acids, triacylglycerols and cholesterol. Insulin increases 
the rate of protein synthesis in many tissues and decreases the rate of protein degradation 
in muscle (12).  
In addition to the metabolic effects, there has been clear evidence that insulin is 
able to induce also growth promoting effects (13-16). People with decreased levels of 
functional IR due to mutations in the IR gene are born with severe growth retardation 
(17,18). Moreover, babies born with diabetes and hypoinsulinemia are short, whereas 
babies that are born with hyperinsulinemia are big (19).  
In organism, insulin is produced in pancreas, specifically in the β-cells of the islets 
of Langerhans. It is synthesized as a single chain precursor, preproinsulin. During the 
processing of the molecule, the signal peptide of preproinsulin is cleaved out, resulting in 
the molecule of proinsulin. The mature insulin is formed from proinsulin in secretory 
granules, where the C-peptide, which connects the A and B chains, is cleaved out (20-22).  
Mature granules contain about 2-3% of non-cleaved proinsulin and the rest of 
equimolar amounts of insulin and C-peptide. Their content is secreted from the pancreatic 
β-cells by exocytosis, which is a blood-glucose level dependent step (22,23). There is 
probably no significant biological function of C-peptide, but it is still a subject of 
discussion and research (24-26). However, the detection of C-peptide in blood is used to 
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determine the rate of endogenous biosynthesis and secretion of insulin. Therefore it serves 
as a valuable diagnostic tool in patients with diabetes mellitus (26). 
It is proposed that proinsulin forms soluble Zn2+-coordinated hexamers in the 
secretory granules, where the pH is set to be aroud 5,5. It is probably the form in which 
proinsulin is converted to insulin. However, the secretion into the blodstream pH 7,4 
causes loss of the hexamer stability which results in a decay of the hexamers (27). The 
active form of insulin is the monomeric insulin that circulates in the bloodstream at 
concentrations lower than 10-9M. However, in addition to the hexamers and monomers, 
insulin forms also dimers above micromolar concentration (28). 
 
1.1.1.2 Insulin-like growth factors: role, biosynthesis and in vivo distribution 
IGFs are hormones that influence many processes in the organism. In the first 
place, they participate in the growth of almost every organ in the body. They play an 
important role during fetal development as well as in postnatal growth and they participate 
in the regulation of life span and longevity.  
IGF-1 was shown to influence both prenatal (29,30) and postnatal (31-33) growth. 
Postnatally, the levels of IGF-1 in human body change with age. It is low after birth, 
increase during childhood and puberty, and start to decrease in adulthood (34,35). IGF-1 
probably plays an essential role in accelerating growth in puberty (31,36): it is a critical 
mediator of skeletal growth (32,37). In adulthood, IGF-1 participates in skeletal muscle 
mass maintenance and regeneration (33) and it is fundamental for bone health throughout 
life (37,38).  
Last but not least, IGF-1 has been shown to have also insulin-like effects on 
maintaining glucose homeostasis. There has been evidence that IGF-1 can stimulate 
glucose transport and has an ability to lower plasma glucose concentration (39-42). 
IGF-2 is much less studied than IGF-1 and its functions in humans are mostly 
unclear despite the fact that IGF-2 is quantitatively predominant form of IGFs in adults 
(about three times more than IGF-1) (43,44). In general, IGF-2 is known to regulate cell 
growth, proliferation, migration and survival and to play a pivotal role in embryonic and  
fetal growth. However, whereas in mice IGF-2 is not expressed after birth anymore, in 
humans it remains expressed throughout whole lifetime (2), which leads to the lack of  a 
suitable model and makes IGF-2 a difficult molecule to study. Nevertheless, IGF-2 was 
shown to play a significant role in human fetal development. Newborns with Beckwith-
Wiedemann syndrome, which is besides other factors characterized also by increased  
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IGF-2 expression, are born overgrown even though they reach normal stature in adulthood 
(3,45) . On the other hand, individuals with Silver-Russel syndrome, and thus with lowered 
IGF-2 expression, are characterized by severe intrauterine growth retardation (46,47).  
Similarly to IGF-1, also IGF-2 appears to be an important modulator of muscle 
growth and differentation (48) and has an impact on skeletal growth (49).  
Unlike insulin, which is a typical endocrine hormone, IGF-1 and IGF-2 are 
produced by variety of tissues and can behave also in paracrine or autocrine manner. IGF-1 
is produced extensively in liver (acting as an endocrine hormone), however its expression 
was observed also in extrahepatic tissues as forebrain, lung, ovary, testes, uterus, kidney, 
heart, mammary glands or skeletal muscle (50). The expression of IGF-1 in adult life is 
induced by growth hormone (GH). In fact, IGF-1 is a mediator of the anabolic and 
mitogenic activity of GH and thus of its action on the target tissues (51). In contrast with 
IGF-1, it was observed that in humans, the IGF-2 gene is active in almost all embryonic 
and fetal tissues, even though the quantity of transcripts differed among organs with the 
highest rate observed in liver, adrenal tissue, kidney and skeletal muscle as well as tongue. 
The transcription of IGF-2 gene decreases rapidly in most tissues after birth. In adult 
humans it was found to be expressed in liver, heart, kidney, spleen or lung (52). The 
production of IGF-2 is not under the control of GH.  
Similarly to insulin, IGFs are first synthesized in the form of precursors that are 
afterwards processed further on both ends. The IGF-1 and IGF-2 genes provide several 
transcripts that in case of each hormone share the same signal sequences and differ in the 
C-terminal parts. After the cleavage of these sequences, mature IGFs are formed (53-55). 
IGF-1 and IGF-2 can be bound by six IGFBPs in vivo. IGFBPs are structurally 
related proteins that share a large part of their aminoacid sequences. These proteins are 
present in circulation and also in extravascular fluids and they regulate the bioavaibility 
and activity of IGFs (2,56,57). They bind IGFs with high affinity and thus only a small 
amount of IGFs (about 1%) is present in the free form in the body fluids (58).  
 
1.1.2 Receptors of the insulin/IGF system 
IR and IGF-1R are membrane proteins that, similarly to the ligands of the 
insulin/IGF system, share high homology in their structures. They belong to the 
superfamily of receptor tyrosine kinases (RTKs) (59). Both IR and IGF-1R consist of two 
α and two β subunits. These subunits are covalently linked forming a dimeric 
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(heterotetrameric) (αβ)2 arrangement (see also chapter 1.2.3 and figure 4 on page 27). 
While the α subunits are exclusively extracellular and they hold the binding site for the 
ligand, the β subunits span the membrane and contain the tyrosine kinase domain in their 
intracellular parts.  
Due to the high similarity between IR and IGF-1R, in cells co-expressing both of 
the receptors, hybrid forms that consist of one αβ monomer of one type of receptor and the 
other αβ monomer of the other type of the receptor can be formed (5,60). The 
physiological role of the hybrid receptors is not completely understood up to date. It was 
shown that the IGF-1R/IR hybrids have binding properties very similar to IGF-1R, which 
means that they bind IGF-1 with high affinity and insulin with much lower affinity (61). 
The presence of the hybrid receptors in a variety of mammalian tissues (60) makes the 
whole insulin/IGF system even more complex and not easy to understand.  
 
1.1.2.1 Insulin receptor (IR-A and IR-B): role, biosynthesis and in vivo distribution 
In organism, IR is synthesized as a single polypeptide chain that is further post-
translationally modified to form the mature receptor. The post-translational modifications 
include proteolytical cleavage of the original precursor chain, creating the individual α and 
β subunits, and their disulphide linkage and extensive glycosylation (62,63). IR exists as 
two isoforms, IR-A and IR-B, which originate due to the alternative splicing of the Ir gene, 
specifically of its exon 11 (64). These isoforms differ only in 12 aminoacids in the  
C-terminal region of α subunit (so called αCT, see chapter 1.2.3), that are present in IR-B 
but not in IR-A. There is not any difference in the β subunits of the two isoforms of IR.  
The function of IR-A and IR-B is considered to be slightly different. The first factor 
playing a role in this diversification is the tissue distribution of both isoforms. While IR-B 
is expressed predominantly in the insulin sensitive tissues (liver, adipose tissue and skeletal 
muscle), IR-A was found in significant amounts also in other tissues, as brain, heart, 
pancreas or spleen as well as in different types of fetal tissues (64-66). Another factor that 
contributes to the specific roles of IR-A and IR-B is their different affinity for the ligands 
of the insulin/IGF system. As it is shown in table 1 (page 18), the affinity of both IR 
receptor isoforms for insulin differs only slightly, however, both IGFs bind one magnitude 
stronger to IR-A than IR-B and in case of IGF-2 this affinity is comparable to that one for 
IGF-1R, making this hormone a ligand for both IGF-1R and IR-A (66-69). Moreover, there 
has been evidence for different signaling outcomes after activation of IR-A and IR-B 
(70,71). This will be discussed in more detail further (see chapter 1.4.5). For all these 
 23 
reasons, IR-B is considered to be rather the “metabolic” isoform of insulin receptor, 
whereas IR-A is supposed to promote also significant “mitogenic” effects.  
 
1.1.2.2 IGF-1 receptor: role, biosynthesis and in vivo distribution  
The biosynthesis of IGF-1R is known to be analogical to that one of IR, including 
the furin cleavage of a precursor protein, formation of disulphide bonds among the 
subunits and glycosylation (72,73). The Igf-1r gene does not contain any homolog to the 
alternatively spliced exon 11 of the Ir gene (74).  
As its name suggests, IGF-1R is predominantly involved in inducing cell growth 
and proliferation (2,75). The different functions of IR and IGF-1R are clearly demonstrable 
on mice models, as the mice lacking IGF-1R display pronounced growth retardation and 
die shortly after birth due to respiratory insufficiency and failure to thrive (75). On the 
other hand, mice lacking IR exhibit only slight growth retardation and die within the first 
week of life from severe hyperglycemia and diabetic ketoacidosis (76,77). However, there 
has been evidence that IGF-1R can mediate also metabolic effects as glucose uptake or 
glycogen synthesis (40,78).  
Unlike IR, IGF-1R was found to be expressed in almost all human tissues (2,33). 
As it is illustrated in table 1, IGF-1R has high affinity for IGF-1, about 10 times lower 
affinity for IGF-2 and low affinity for insulin (67,69,79,80).  
 
1.2 Structure 
1.2.1 Primary structure of the ligands 
The aminoacid sequence of human insulin was solved in 1960 by Nicol et al. (9).  
It is a 51 aminoacids long two chain peptide – the A chain contains 21 aminoacids and the  
B chain contains 30 aminoacids. The A and B chains are interconnected by two disulphide 
bonds (CysA7-CysB7 and CysA20-CysB19). A third disulphide bond is present within  
the A chain (CysA6-CysA11) (see figure 2A).  
Unlike insulin, maturated human IGF-1 and IGF-2 are single chain peptides that 
contain 70 and 67 aminoacids, respectively (10,11).  Their sequences are divided into four 
domains: B, C, A and D (written in order from the N to the C-terminus, see figure 2).  
The A and B domains of both IGFs are analogous to the A and B chains of insulin and they 
share about 50% of the aminoacid sequence with them. There is about 70% mutual 
sequence homology between  the A and B domains of IGF-1 and IGF-2.  
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Both IGF-1 and IGF-2 contain analogous disulphide bonds to that ones present in 
insulin: Cys6-Cys48, Cys18-Cys61 and Cys47-Cys52 in case of IGF-1 and Cys9-Cys47, 
Cys21-Cys60 and Cys46-Cys51 in case of IGF-2 (see figure 2A).  
The C and D domains of IGF-1 and IGF-2 do not have their analogous counterparts 
present in the molecule of insulin. The C domain is inserted between the A and B domains 
and even though it is analogous to the C-peptide of proinsulin, there is not any significant 
aminoacid similarity between any of the IGF´s C domains and the C-peptide (10,11,21). 
There is a significant homology between the C and D domains of IGF-1 and IGF-2. The 
direct comparison of the aminoacid sequences of insulin and both IGFs is shown  
in figure 2B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Primary structure of human insulin, IGF-1 and IGF-2. Single letter codes of 
aminoacids are used. A: Schematic representation of the ligands with the disulphide bonds 
indicated. The A chain/domain is in blue, the B chain/domain is in grey, the C domain is in 
red and the D domain is in yellow. B: Comparison of the aminoacid sequences of the 
ligands. The organization of the B, C, A and D domains (B and A chains in insulin)  
is shown below the sequences. The homologous regions between all three hormones  
are highlited in grey and the additional homologous regions between IGF-1 and IGF-2  
are highlited by black boxes. The image B was adapted from (81). 
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1.2.2 Tertiary structure of the ligands 
The three-dimensional structure of insulin has been extensively studied (28,82-88) 
since the discovery of the hormone in 1922 (89). There are significant secondary motifs 
forming the molecule of monomeric insulin. The B chain consists of a central α-helix 
(SerB9–CysB19) flanked by a β-turn from each side (CysB7–HisB10 and  
GlyB20–GlyB23). The C-terminal segment of the B chain (GlyB23–ThrB30) forms  
a β-strand structure that is oriented in close proximity and antiparallel to the central  
α-helix. The A chain contains two antiparallel α-helical segments (GlyA1–ThrA8 and 
SerA12–TyrA19) connected by a non-canonical turn (SerA9–SerA12). This arrangement 
results in a close proximity of the A chain N and C-termini. The three-dimensional 
structure of human insulin monomer is shown in the figure 3.  
Both IGF-1 and IGF-2 share the same main secondary structure motifs with the 
molecule of insulin (90-93), as it is shown in figure 3. They consist of a hydrophobic core 
formed by three α-helices. In both cases the first one is present within the B domain and 
corresponds to the insulin B chain α-helix, whereas the remaining two are present within A 
domain and correspond to the A chain α-helices. The C and D domains of both hormones 
appear highly flexible in the structures determined by NMR spectroscopy (90,91,93). 
 
Figure 3: Three-dimensional structure human insulin, IGF-1 and IGF-2.  
B chain/domains are in blue, C domains are in red, A chain/domains are in green and  
D domains are in magenta. The disulphide bridges are coloured in yellow. The C- and  
N-termini are indicated. Insulin: PDB code 1MSO, IGF-1: PDB code 2GF1, IGF-2: PDB 
code 1IGL. 
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1.2.3 Domain composition and primary structure of the receptors 
IR and IGF-1R are highly similar receptors that share the same subunit and domain 
composition as well as a big part of their aminoacid sequences (72,73). They are 
extensively glycosylated (62,73). 
The α subunits of IR and IGF-1R are about 130 kDa big. They consinst of two 
homologous globular leucine rich domains (L1 and L2), that are separated by a cysteine 
rich region (CR) (94,95). These are followed by two fibronectin type III domains (FnIII-1 
and FnIII-2) (96) of which the second one is split by an insert domain (ID). ID holds the 
proteolytic furin cleavage site in the original receptor precursor and thus in the molecule of 
the mature receptor its second part already forms the β subunit. The ID also contains three 
disulphide bonds that connect together the two α subunits of the receptor dimer (97,98).  
An additional disulphide bond holding together α subunits is present within the FnIII-1 
domains (98). In case of IR-B, the additional 12 aminoacids, that differentiate it from  
IR-A, are inserted in the C-terminal region of the ID domain (so called α C-terminal 
peptide (αCT)) (see figure 4).  
The β subunits of IR and IGF-1R are about 95 kDa big. Their extracellular part is 
formed by the remaining parts of ID and FnIII-2 and another fibronectin type III domain 
(FnIII-3) (99). These are followed by a transmembrane domain (TM) that spans the 
membrane. The intracellular part of the β subunits is formed by a juxtamembrane domain 
(JM), the catalytically active tyrosine kinase domain (TK) and a C-tail in the C-terminal 
part. JM and C-tail contain the tyrosine residues, that, upon their phosphorylation, create 
the binding sites for the downstream signaling molecules (97,100). There is a disulphide 
bond connecting together the α and β subunit within each αβ dimer, specifically it is 
formed between the FnIII-3 domain of the β subunit and the FnIII-2 domain of the  
α subunit (98). The domain composition of the whole receptors is schematically shown in 
the figure 4.  
The similarity in the aminoacid sequence between IR and IGF-1R varies among 
domains from 41 to 84%. The highest homology (84%) was found within the tyrosine 
kinase domains. High homology (64 to 67%) was found also in the L1 and L2 domains that 
are involved in ligand binding. The similarity is lower (48%) within the cysteine rich 
regions, however the majority of the cysteine residues are conserved among IGF-1R and 
IR. The lowest degree of similarity was found within the transmembrane domains (73). 
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Figure 4: Schematic representation of the subunit and domain composition of IR and 
IGF-1R. α – α subunit, β – β subunit, L1, L2 – leucine rich domains 1 and 2,  
CR – cysteine rich region, FnIII-1, FnIII-2, FnIII-3 – fibronectine type III domains 1, 2 and 
3, ID – insert domain, αCT – C-terminal region of the α subunit which containst  
the alternatively spliced 12 aminoacids in IR-B but not IR-A, TM – transmembrane 
domain, JM – juxtamembrane domain, TK – tyrosine kinase domain, C-tail – C-terminus 
of β subunit. The image was adapted from (97). 
 
1.2.4 Three-dimensional structure of insulin and IGF-1 receptors  
Up to this date, there have been several crystallographic studies of IR and IGF-1R 
constructs shedding light on the receptors’ structures. The IR unligated ectodomain was 
crystalised in 2006 (101) and further resolved in 2010 (102). Analogous structure of  
IGF-1R was solved in 2018 (103). Besides that, there are crystal structures of L1-CR-L2 
constructs of both IR (104) and IGF-1R (105). 
There are also several crystal structures of IR and IGF-1R TK domains in their  
non-phosphorylated and phosphorylated states (106-109).  
 
1.2.4.1 Structure of the receptors’ ectodomains 
Each monomer of IR and IGF-1R ectodomain adopts an inverted V arrangement in 
respect to the cell membrane, where one leg of the V is formed by L1, CR and L2 domains, 
whereas the other is formed by the three FnIII domains. The connection between the L2 
and FnIII-1 domains lies at the apex of the inverted V. The C-termini of the FnIII-3 
domains are oriented towards the membrane where the transmembrane domains follow. 
The two monomers that form the receptor ectodomain are related to each other in an 
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arrangement where the L1-CR-L2 domains of one mononer are packed against the three 
FnIII domains of the other monomer. At the apex of the ectodomain, the L2 domain of 
each monomer contacts the FnIII-1 domain of the other one (101,103). The representations 
of crystal structures of IR and IGF-1R ectodomains are shown in figure 5.   
Despite the high similarity of the structures of both receptors’ ectodomains, there 
are also some significant differences between the receptors. Fist, the overall shape  
of IGF-1R seems to be more closed than the one of IR, as the sites of the membrane entry  
(at the C-termini of the FnIII-3 domains) are substantially closer together in IGF-1R than 
in IR (101,103) (see figure 5). This may simply be a consequence of flexibility at the 
interdomain boundaries and their packing into different crystal lattices, or it may reflect 
different structures of the two receptors possibly related to their different mode of 
activation (103).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Crystal structures of IR and IGF-1R ectodomains. L1 domain is in light blue, 
CR domain is in red, L2 domain is in orange, FnIII-1 domain is in green, FnIII-2 domain is 
in yellow, FnIII-3 domain is in blue, ID is in light magenta and αCT is in magenta.The 
foreground monomers are in ribbon representation and the background monomers are in 
surface representation. Dashed lines indicate disordered residues within ID. The images 
were reproduced from (103).  
 
A difference was also found in the position of the C-terminal part of αCT. In both 
receptors, the central part of this segment is α-helical and has extensive contacts with the 
central β-sheet of L1 domain. However, whereas in IR the C-terminal part of αCT is 
entirely disordered and directed away from the FnIII-2 domain of the other receptor 
 29 
monomer, in IGF-1R it packs against the surface of the corresponding FnIII-2 domain 
(101-103) (see figure 6). 
 
 
 
 
 
 
 
 
Figure 6: Configuration of the αCT and domains L1 and FnIII2 in the ectodomains  
of IR and IGF-1R. L1 domain (blue) belongs to one receptor monomer and αCT´ 
(magenta) and FnIII-2´ (yellow) belong to the other receptor monomer. Green dashed line 
represents the disordered C-terminal region of αCT in IR. The image was reproduced  
from (103). 
 
The structures of the L1-CR-L2 constructs of IR and IGF-1R, besides similarities, 
also reveal certain differences between the receptors, that are present mostly in the regions 
that are known to be crucial for ligand specificity (see chapter 1.3.1). The largest 
difference in the two structures was seen in a part of the CR region (see figure 7A), where 
is no sequence identity between the two receptors. This part shows a difference in the 
electrostatic potentials. While in IR it is predominantly positive, it shows more negative 
pattern in IGF-1R (see figure 7B). The second significant difference in aminoacid 
composition between IR and IGF-1R was observed in a part of the L1 domain  
(see figure 7A) (97,104). 
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Figure 7: Comparison of the L1-CR-L2 fragments of IR and IGF-1R. A: Crystal 
structures of the L1-CR-L2 constructs. Two notable regions of difference between IR and 
IGF-1R are indicated by box (the area in the L1 domain) and circle (the area in the CR 
domain). B: Comparison of the electrostatic potential in the L1-CR-L2 region of IR and 
IGF-1R. The images were reproduced from (104). 
 
1.2.4.2 Structure of the receptors’ intracellular parts  
Regarding the intracellular portion of the receptors, its largest part is formed by the 
catalytic tyrosine kinase domain that is crucial for the receptor function. The tyrosine 
kinase domains of IR and IGF-1R share the highest aminoacid sequence similarity among 
all the domains of the receptors (84%) (73).  
 The TK domain of IR and IGF-1R are composed of two lobes – smaller N-terminal 
lobe and larger C-terminal lobe. The activation loop that is crucial for receptor 
autophosphorylation and thus activation is present within the C-terminal lobe (106-109).  
 
1.3 Binding of the hormones to their receptors 
The binding of insulin and IGF-1 to their receptors is a complex process that 
requires extensive changes in the structure of both the hormones and the receptors. 
Although the character of the binding has been a subject of research for decades, it is still 
not completely characterized and understood.  
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1.3.1 Structural determinants involved in ligand-receptor interactions 
It was established that there are two distinct binding sites within the receptors: the 
primary binding site (Site 1, its Kd for insulin on IR is ~ 6.4 nM) and the secondary binding 
site (Site 2, its Kd for insulin on IR is ~ 400 nM) (110). Binding of a hormone to both sites 
on the receptor is crucial for high affinity ligand binding (Kd for insulin on IR is ~ 0.4 nM, 
see table 1 (page 18)). 
   The Site 1 of IR and IGF-1R has been well characterized and positioned to the 
central β-sheet of L1 domain of one subunit and αCT peptide of the other receptor subunit 
(97,103,110-114). The Site 2 on IR and IGF-1R is located on the alternate receptor 
monomer to that which contributes the L1 domain that forms site 1. In IR, based on 
mutagenesis and computational studies, it was previously positioned within the residues of 
FnIII-1 and L2 (115,116) or near the junction of FnIII-1 and FnIII-2 domains (97,101,117), 
but recent single-particle cryo-EM studies position it within the FnIII-1 domain only 
(118,119). Regarding IGF-1R, the location and role of Site 2 remain uncertain (103).  
It remains possible that the IGF-1R Site 2 is located in different parts of the receptor 
compared to IR.  
Two surfaces in insulin and IGF-1 are understood to interact with the receptor.  
In insulin, the so called “classical binding surface” contacts the Site 1 of the receptor. It is 
composed predominantly of the residues forming the dimer-forming face of insulin, 
comprising GlyA1, IleA2, ValA3, GlnA5, TyrA19, AsnA21, ValB12, TyrB16, GlyB23, 
PheB24, PheB25 and TyrB26 (110,114,120,121). The involvement of these residues in 
receptor binding was confirmed by the crystallographic studies of the insulin:IR complex 
(110,114). The second surface in insulin, which contacts the receptor Site 2, was 
previously mapped to involve residues overlapping with the hexamer-forming face of 
insulin, containing ThrA8, IleA10, SerA12, LeuA13, GluA17, HisB10, GluB13 and 
LeuB17 (122-124). However, the recent cryoEM studies limited it to some residues within 
the first A chain α-helix (CysA7, ThrA8) and B chain residues GlnB4-GlyB8, HisB10 and 
possibly GluB13 only (118,119). The role of the remaining residues IleA10, SerA12, 
LeuA13, GluA17 and LeuB17, whose mutations diminish insulin binding, therefore lies 
elsewhere and will need further clarification. It is possible that these residues may be 
involved in the initial docking of insulin to the receptor (119). 
In IGF-1, several residues structurally corresponding to the residues of the insulin 
Site 1 have been also found to be important for binding to IGF-1R. Specifically, it is Phe23 
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(corresponding to insulin residue PheB24), Tyr24 (PheB25), Val44 (ValA3), Tyr60 
(TyrA19) and Ala62 (AsnA21) (79,125-127). Similarly, residues corresponding to the 
previously proposed insulin Site 2 that are important for high affinity binding of IGF-1  
to IGF-1R have been identified, comprising Glu9 (insulin HisB10), Asp12 (GluB13), 
Phe16 (LeuB17), Leu54 (LeuA13) and Glu58 (GluA17) (128). In addition, some other 
residues without its homolog in insulin molecule have been found to be involved in 
receptor binding, including Ala8, Met59 and some C domain residues as Tyr31, Arg36 and 
Arg37 (79,125,129) .  
 
1.3.1.1 The role of the C and D domains of IGFs in receptor binding 
The C and D domains of IGF-1 and IGF-2 represent the major structural differences 
between these growths factors and insulin as well as between both IGFs themselves (9-11). 
It is tempting to expect that they play important roles in the differential binding of the 
hormones to the receptors, which has been supported by research of IGF and insulin-IGF 
chimeras. 
When the C and D domains were exchanged between IGF-1 and IGF-2, it was 
demonstrated that especially the C domain, and to a lesser extent the D domain, are the 
principal determinants responsible for the higher affinity of IGF-2 to IR-A compared to 
IGF-1. These domains influence the binding of the hormones to IR-B similarly as well, 
even though the overall affinity of both hormones to this receptor is lower. The importance 
of these domains to IGF-1R binding was also shown, as the affinity of IGF-2 chimera 
containing the C and D domains derived from IGF-1 was more IGF-1-like and vice versa 
(67).  
Some insulin-IGF chimeras were also prepared. A negative impact of the IGF-1 D 
domain to IR binding was demonstrated by an insulin analog that contained the IGF-1 D 
domain connected to the C-terminus of the A chain. The affinity of this analog for IR on 
rat adypocytes was only 28% compared to native insulin (130). On the contrary, in case of 
the IGF-1 C domain, it was shown that it does not have negative effect on insulin binding, 
as the affinity of a single chain insulin chimera containing the IGF-1 derived C domain 
was 113% compared to insulin (80). However, a different result was achieved with a two-
chain insulin analog in which the eight last C-terminal aminoacids of the B chain were 
substituted by the analogous residues derived from IGF-1 and the following C domain was 
attached, which showed an IR affinity decreased to 28% compared to insulin. On the 
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contrary, the affinity of this analog for IGF-1R was increased 80 times when compared to 
insulin (131).  
 
1.3.1.2 The role of the C-terminus of insulin B chain in receptor binding  
The C-terminus of insulin B chain was shown to play a crucial role in IR binding. 
The deletion of the eight C-terminal aminoacids of the insulin B chain leads to about 2,500 
fold decrease in the binding affinity (unpublished data from our laboratory). Especially the 
three aromatic aminoacids PheB24, PheB25 and TyrB26 are among the key residues in 
receptor binding. Even though the residues in the positions B26 to B30 are not necesarry 
for full binding (132), it was shown that the role of TyrB26 in binding is not negligible as 
its replacement with various aminoacids resulted in a a wide range of binding affinities, 
from weak to “superpotent” analogs (133-136).  
PheB24 and PheB25 were shown to be crucial for receptor binding (132).  
The position B24 does not tolerate L-aminoacid substitutions, whose introduction in most 
cases leads to complete or very significant loss of the binding affinity (137-141). The only 
exception is glycine (140,142,143). Similarly, the PheB25 was shown to be crucial for 
receptor binding by numerous mutagenesis studies (132,137,144-146). 
Suprinsingly, the substitutions with D-aminoacids in the position B24 are well 
tolerated resulting in even increased affinities compared to insulin (140,141,147). Previous 
results from our laboratory showed that while the [HisB24]-insulin is almost inactive 
regarding IR binding, the affinity of [D-HisB24]-insulin reaches 212% compared to insulin 
(141). It wash shown that in the [D-HisB24]-nsulin structure, the diverse chirality of the  
D-His enables the following residues to shift  one position down compared to native 
insulin. PheB25 occupies the position that corresponds to PheB24 in native insulin and 
similarly, TyrB26 occupies the position that corresponds to PheB25. Therefore, the 
aromatic character of the invariant residues B24 and B25 is preserved. Also, the diverse 
chirality in the position B24 results in higher flexibility of the C-terminal part of insulin  
B chain, which can, in accorandce with a so called “detachment model”, contribute to the 
higher receptor affinity (141). The detachment model was proposed in the past by many 
studies (134,141,148-151) and it suggested that upon insulin binding, the C-terminus of the 
B chain departs away from the mostly hydrophobic helical core of the hormone, 
uncovering its residues and enabling them to interact with the receptor. This was 
afterwards confirmed by the results of insulin cocrystalised with its receptor (110,114) (see 
also chapter 1.3.3.1). 
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1.3.2 Binding kinetics and negative cooperativity 
As it is evident from the receptor dimeric structure, there are two Sites 1, two Sites 
2 and thus two complete high affinity binding sites within each receptor dimer. However, it 
is known that the receptor binds only one molecule of ligand with high affinity. Only at 
saturation concentrations it can bind another two molecules with low affinity 
(97,103,122,123,152) (see figure 8B).  
The binding of insulin and IGF-1 to their receptors is characterized by negative 
cooperativity (120,122,152-156), which means that binding of a hormone to one of the two 
high affinity binding sites lowers the affinity of the other one.  
Despite high similarities between the two receptors described above, a difference in 
their behaviour has been observed. In case of IR, the dose-response curve for accelerated 
dissociation of the radiolabeled ligand in presence of increasing concentrations of  
non-labeled ligand is bell-shaped: the dissociation first increases reaching its maximum at 
100 – 1000 nM, but it decreases again at higher concentrations (see figure 8A). This 
indicates that at very high (supraphysiological) concentrations, the second and third ligand 
molecules can bind to both free Site 1 and Site 2, preventing the second crosslinking of the 
receptor and the dissociation of the first ligand molecule bound the complete high affinity 
binding site (see figure 8B) (120,122,153,154,156). However, such behaviour was not 
observed for IGF-1R, where the accelerating effect of unlabeled IGF-I reached  maximum 
at around 100 nM IGF-I, but remained stable up to the highest concentration tested  
(see figure 8A) (103,152,155). This indicates that although the IGF-1R retains the property 
of negative cooperativity, it probably lacks the ability to “lock” the first ligand molecule in 
the first binding site at high ligand concentrations, as is the case for IR.  
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Figure 8: Negative cooperativity. A: The dose-response curves for accelerated 
dissociation of radiolabeled ligand (insulin or IGF-1) from their receptors (IR and IGF-1R, 
respectively) induced by non-labeled ligand (insulin or IGF-1) as published in (4).  
B: Schematic representation of negative cooperativity at IR (adapted from (157)). 
 
1.3.3 Structural changes upon ligand binding and receptor activation 
The character of the interaction of the hormones with their receptors, its structural 
consequences and eventual differences between the insulin:IR and IGF-1:IGF-1R 
interaction,  have been a subject of investigation for decades. However, structural studies 
of the IR and IGF-1R were prevented for a long time due to their large size, flexible 
multidomain morphology and extensive glycosylation and disulphide bonding that pose 
challenges in production and crystallization (110). The cocrystallization of the hormones 
bound to their receptor is even more challenging. Therefore, the understanding of the 
character of the interactions was based solely on mutagenesis and crosslinking studies until 
the first crystal structure of insulin bound to an IR homodimeric construct was published in 
2013 (110). The construct contained the L1, CR, L2 and FnIII-1 domains and the αCT 
linked to the FnIII-1. Since that time, further studies shedding light into the problematics 
have been revealed (103,114). However, whereas the characters of the interactions of 
insulin and IGF-1 with the Sites 1 of their receptors are nowadays well characterized, the 
questions regarding their interactions with Sites 2 as well as how exactly is the signal 
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transmitted to the intracellular parts of the receptors, remain not completely answered 
despite the recent cryo- EM studies (118,119).  
 
1.3.3.1 Changes in the structure of the hormones and receptors´ ectodomains 
The exact nature of the interaction of insulin with the Site 1 on IR was revealed in 
the study of Menting et al. from 2013 (110). This work confirmed the interaction of insulin 
B chain α-helix (residues B7-B21) with the β2 strand of the receptor L1 domain as well as 
extensive interactions of both insulin chains with αCT (see figure 9A). The C-terminus of 
insulin B chain (residues B22-B30) was not resolved in this work, but the αCT helix 
clearly occupied the volume that would otherwise contain insulin residues B25-B30, 
supporting the detachment model (see chapter 1.3.1.2), which has been proposed by many 
studies (134,141,148-151). The work from 2013 was further refined a year later (114)  and 
confirmed that the insulin B chain C-terminal β-turn (residues B20-B23) and β-strand  
(B24 – B27) depart away from the α-helical core of insulin to enable its conserved motif 
(PheB24 – PheB25 – TyrB26) to dock between L1 and αCT. This enables the conserved 
nonpolar residues IleA2, ValA3, ValB12, PheB24, PheB25 and TyrB26 to engage the 
receptor. 
The series of conformational changes taking place upon insulin binding to Site 1 
thus couple detachment of the insulin B chain C-terminus with repositioning of the 
receptor αCT helix on the L1-β2 surface and its insertion into the volume that is in the free 
hormone occupied by its residues B25-B30. In contrast to the C-terminus of insulin  
B chain, the helical core of the hormone seems to be closely similar to that one of 
unbounded insulin (see figure 9B) (110,114).  
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Figure 9: The mode of engagement of insulin with the IR Site 1: A: Insulin bound to 
the Site 1 of IR. Insulin A chain is in grey, insulin B chain is in black, L1 domain of IR is 
in light blue, CR domain is in red and αCT peptide is in magenta. The image was 
reproduced from (103). B: The key structrural transitions taking place upon ligand binding. 
Insulin A chain is in yellow, insulin B chain is in black (transclucent: receptor free 
conformation, solid: receptor bound conformation), the αCT peptide is in magenta 
(transclucent: receptor free conformation, solid: receptor bound conformation), and 
receptor L1 and CR domains are in light blue. The dashed arrow indicates the movement of 
insulin B chain C-terminus upon ligand binding. The image was reproduced from (158).  
 
A cryo-EM study of insulin bound to IR ectodomain dimer, that was published in 
2018 by Scapin et al., confirmed the engagement of site 1 in the interaction, including the 
C-terminal region of the insulin B chain (118). This work also reported the full site 2 and 
its interaction with the hormone. However, the site 2 proposed in this work (positioned to 
FnIII-1 domain only) was much more restricted compared to the assumptions by previous 
mutagenesis and computational studies (97,101,115-117) (see chapter 1.3.1), and the 
insulin receptor dimer identified in the cryo-EM analysis did not resemble the 
crystallographic symmetry-generated dimer (101,118). Nevertheless, another cryo-EM 
study published later in 2018 confirmed these results (119). It also revealed that upon 
ligand binding to both Sites, the FnIII-1, FnIII-2 and FnIII-3 are no longer in the inverted 
V conformation and instead they are folded inwards, which brings the two FnIII-3 domains 
into contact and gives the receptor rather a “T” shaped conformaition. The conformation 
change leading to receptor activation is schematically shown in figure 10. 
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Figure 10: Schematic representation of the proposed mechanism of receptor 
activation. The image was adapted from (159). 
 
The first structure of IGF-1 engagement with the IGF-1R Site 1 was published in 
2018 (103) and the changes observed in the structure of the hormone as well as the 
receptor largely mimic those seen for insulin and IR. They include remodeling of the αCT 
helix on the L1 β2 surface and folding out of the C-terminal region of the IGF-1 B domain 
away from the hormone core. According to the uncertain nature of IGF-1R Site 2  
(see chapter 1.3.1), there has not been any conclusive information about the interaction of 
IGF-1 with site 2 up to date. 
 
1.3.3.2 Changes in the structure of the receptors´ intracellular parts and their 
activation 
The changes in the structure of receptor ectodomain after ligand binding are further 
transmitted to the transmembrane and intracellular parts of the receptor, which enables 
triggering of the downstream signal propagation.  There are several studies supporting the 
model in which the transmembrane domains of both IR and IGF-1R are held apart in the 
absence of ligand while ligand binding allows them to come together. This conformational 
change facilitates autophosphorylation of the cytoplasmic tyrosine kinase domains 
(103,159,160). A schematic representation of these changes is shown in figure 10. 
Several tyrosine residues in the intracellular part of the receptors were shown to be 
autophosphorylated upon the receptor activation in both IR and IGF-1R (161,162). These 
include a conserved triad of tyrosines in the activation loop of the kinase domain (Tyr1158, 
Tyr1161 and Tyr1162 in IR (IR-B numbering) and Tyr1131, Tyr1135 and Tyr1136 in  
IGF-1R). These residues are critical for activation of the TK domain and  stimulation of the 
biological function (161,163-165). Their phosphorylation promotes conformational 
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changes that finally allow ATP and downstream protein substrates to access the kinase 
active site (107,108). 
Besides others, also Tyr 972 in IR (IR-B numbering) and Tyr 950 in IGF-1R within 
the JM domain is autophosphorylated (161,162). This residue is situated within a 
conserved NPEY motif, which is crucial for the binding and further phosphorylation of 
various downstream substrates (166-171). 
 
1.4 Downstream processes and signaling 
Activation of the receptors of the insulin/IGF system leads to the activation of 
multiple downstream effectors that transmit the signal to a series of intracellular pathways. 
Insulin and IGF-1 receptor share a variety of intracellular substrates as well as the two 
main signaling pathways that are triggered upon activation. These are phosphatidylinositol 
3 kinase (PI3K)/Akt signaling pathway (see chapter 1.4.2) and Ras/mitogen activated 
protein kinase (MAPK) signaling pathway (see chapter 1.4.3) (162,170-173).  
 
1.4.1 Intracellular substrates of IR and IGF-1R 
Proteins belonging to the insulin receptor substrate (IRS) and Src homology 
collagen (Shc) families are being recognized as the major substrates of IR and IGF-1R 
(162,170-172). All of them contain a phosphotyrosine binding (PTB) domain, which binds 
to the NPEpY motif of the phosphorylated receptor. They act as docking proteins between 
the receptor and a complex network of intacellular signaling molecules that contain a Src 
homology 2 (SH2) domains (162,171,173).  
IRS proteins represent the largest and most diverse family of intracellular proteins 
that bind to IR and IGF-1R. At least 6 IRS proteins (termed IRS1 – IRS6) have been 
identified (174-178). Their phosphorylation by the receptor can lead to activation of both 
the PI3K/Akt and Ras/MAPK pathways (170,172,179-181). There has been evidence that 
the various IRS proteins have complementary rather than redundant roles (173). The 
individual IRS proteins differ in tissue distribution, subcellular localization, kinetics of 
activation and deactivation as well as in the specificity of interaction with downstream 
effectors (170,173,181-183). IRS1 and IRS2 are widely distributed and contribute to the 
signaling of IR and IGF-1R to the highest extent (170). Whereas IRS2 seems to have a 
major role in regulating hepatic insulin action and in controlling pancreatic β-cell 
development and survival, IRS1 seems to be indispensable for actions in skeletal muscle 
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and adipose tissue (173). Research also indicates that IRS2 is apparently a better substrate 
for IR than for IGF-1R (172,184,185).  
Shc proteins are well-established alternative substrates of the IR and IGFR. Three 
isoforms of Shc proteins are known to exist (p46, p52 and p66) (162,186). Compared to 
IRS, Shc proteins are more effectively phosphorylated by other tyrosine kinases than IR 
and IGF-1R, as the sequence flanking the NPEY motif of these receptors is only sub-
optimal for binding of the PTB domain of Shc (170,187). Unlike IRS proteins, the 
phosphorylation of Shc upon receptor binding triggers processes leading to the activation 
of the Ras/MAPK cascade only (162,170,172).  
Several other substrates of IR and IGF-1R have also been characterized. Some of 
these, such as Grb2-associated binders (Gabs) and downstream of kinases (DOKs), seem to 
act as tissue or pathway specific alternatives to IRSs. Others, such as members of the 
SH2B and Cas-Br-M (murine) ecotropic retroviral transforming sequence homologue (Cbl) 
families, engage distinct signaling pathways and may also have roles in receptor regulation 
(170).  
 
1.4.2 PI3K/Akt signaling pathway 
IRS proteins that interact with the receptor are phosphorylated and recruit further 
downstream molecules through the interaction with their SH2 domains (171,172).  
The regulatory subunit of PI3K, known as p85, belongs among these proteins (188,189). 
After its interaction with IRS, p85 associates with the catalytic subunit of PI3K, also 
known as p110. Activated PI3K then catalyzes the formation of the lipid second messenger 
phosphatidylinositol-3,4,5-triphosphate (PIP3) from phosphatidylinositol-4,5-bisphosphate 
(PIP2) (162,189).  
In turn, PIP3 activates phosphatidylinositol dependent kinases (PDKs), which then 
phosphorylate and activate other protein kinases. Perhaps the most critical of PDKs for 
insulin and IGF-1 action is the PDK1, which is responsible for the activation of protein Akt 
(also known as protein kinase B (PKB)) (171,172).  
Akt is an integral component of the signaling pathway and several substrates of this 
protein have been identified. It was shown to phosphorylate the glucose synthase kinase 3 
(GSK3), deactivating it and thus triggering glycogen synthesis (190). Another substrate of 
Akt was shown to be be 6-phosphofrukto-2-kinase (PFK2), linking the pathway with the 
regulation of glycolysis (191). There has been evidence that Akt phosphorylates the Rab 
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GTPase activating protein AS160, which leads to the insulin-stimulated translocation of 
the glucose transporter type 4 (GLUT4) to the plasma membrane of muscle cells and 
adipocytes (192). However, also proteins that are not involved in the carbohydrate 
metabolism are phosphorylated by Akt. Activation of Akt was shown to lead also to the 
inhibition of apoptosis (193,194) as well as stimulation of protein synthesis, which is 
mediated by the phosphorylation of the tuberous sclerosis complex protein 2 (TSC2). 
TSC2 is supposed to lead to the activation of the protein kinase mTOR complex 1 
(mTORC1) (195). Therefore, many diverse cellular processes are believed to be regulated 
by the PI3K/Akt signaling pathway. The PI3K/Akt pathway and its functional outcomes 
are schematically shown in the figure 11. 
 
1.4.3 Ras/MAPK signaling pathway 
The Ras/MAPK signaling pathway, which is coupled mainly to mitogenic and 
transcriptional responses, can be triggered by the interaction of the receptor with both IRS 
(namely IRS1) and Shc proteins (196). After their phosphorylation, these proteins recruit 
the growth factor receptor binding protein 2 (Grb2), that serves as an adaptor molecule for 
the interaction with the guanine nucleotide exchange factor Son of sevenless (Sos) (197). 
Sos catalyses the transition of the inactive Ras-GDP form of the small GTPase Ras to its 
activated Ras-GTP form. That in turn activates the protein serine kinase Raf (162, 
170-172).  
The activation of Raf triggers a kinase cascade that results in the activation MAPK 
and Erk kinases (MEKs), specifically MEK1 and MEK2. These kinases phosphorylate and 
thus activate extracelular signal-regulated kinase 1 and 2 (Erk1 and Erk2), which are proteins 
belonging to the family of MAPKs (171,198).  
Activated Erks phosphorylate numerous substrates in all cellular compartments.  
At least 280 substrates have been identified in a proteomic screening (199), including a 
variety of nuclear transcription factors and kinases as well as proteins with anti-
proliferative effects and other proteins that participate in the regulation of cell growth, 
proliferation, differentiation, adhesion, migration and survival (171,198,200,201). The 
Ras/MAPK pathway and its functional outcomes are schematically shown in the figure 11. 
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Figure 11: Schematic representation of the PI3K/Akt and Ras/MAPK pathways and 
their functional outcomes. The dashed arrow represents a multistep process.   
 
 
1.4.4 Receptor internalization 
Besides the activation of the signaling pathways, the autophosphorylation of IR and 
IGF-1R triggers also the internalization of the receptors to the endosomal apparatus of the 
cell. That leads to the termination of the signal, as the acidic pH of the endosomes causes a 
rapid dissociation of the ligand from the receptor. The ligand is afterwards degraded 
(170,202). 
The receptors are mostly recycled back to the membrane. However, they can also 
translocate into lysosomes for degradation, which seems to be the case especially under 
prolonged stimulation or receptor saturating doses of the ligand (170,202).  
The internalization of the receptor also seems to play a role in signaling. There has 
been evidence that the IR and IGF-1R mediated phosphorylation of Shc proteins is 
receptor internalization dependent (203,204). Research indicates that the rate of 
internalization influences also further processes of the downstream signaling (205,206).  
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1.4.5 Diversification of the function and signaling from IR-A, IR-B and IGF-1R 
How and when is the function of the ligands and receptors of the insulin/IGF 
system diversified is still not completely understood. Probably factors such a tissue 
distribution of the receptors, their number at the cell surface as well as specific background 
in the given cell play a role.  
However, differences between IR isoforms regarding signaling upon stimulation of 
the same ligand and within the same cell background have been reported in various cell 
types. It was shown that in pancreatic cells, the transcription of the β cell glukokinase gene 
is regulated by different signaling mechanisms upon insulin stimulation of IR-A and IR-B 
(70). Data obtained in murine 32D hemopoietic cells indicate that upon stimulation of  
IGF-2, IR-A preferentially induces mitogenic and antiapoptotic signals, whereas IR-B 
predominantly induces cell differentiation (71). 
Research also indicate that different ligands can trigger different responses upon 
stimulation of the same receptor type. For example, when the R-/IR-A mouse enbryonic 
fiboblasts, that express IR-A only, are stimulated with IGF-2, they preferentially undergo 
proliferation, while they preferentially activate glucose uptake when stimulated with 
insulin (66,207). In SKUT-1 human leiomyosarcoma cells, that also express functional  
IR-A only, IGF-2 seems to stimulate the Ras/MAPK pathway and cell migration more 
potently than insulin, whereas insulin seems to be a more potent stimulator of the 
PI3K/Akt pathway and a better protector from apoptosis (208). It was also reported that 
insulin and IGF-2 induce differential gene expression after IR-A stimulation (209). A study 
also showed that a synthetiC-peptide, which binds to IR-A with similar affinity as insulin 
but interacts with the receptor in a different manner, triggers different signaling outcomes 
and gene expression than insulin (210).  
Regarding the IGF-1 receptor, it was shown that at equal concentrations, insulin 
and IGF-1 regulate the expression of the same genes, however insulin does that with a 
smaller magnitude of response than IGF-1 (211). However, another study, in which the 
cells expressing IGF-1R only were stimulated with equipotent saturating concentrations of 
insulin, IGF-1 and IGF-2, showed that each ligand specifically regulated a group of 
transcripts that was not regulated by the other two ligands (212).  
The factors involved in the above described diversification of the function may 
involve different efficiency with which the receptors recruit the intracellular substrates. 
However, because both Shc and IRS can recruit Grb2/Sos and thus activate the  
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Ras /MAPK pathway (see chapter 1.4.3), the situation seems to be more complex. Also, 
different affinities of individual activated receptors for different downstream substrates 
would not explain the differential signaling arising from the same receptor type upon 
activation by different ligands.  
 
1.4.5.1 Kinetics as the factor influencing downstream signaling 
Therefore, a concept has emereged that the kinetic aspect of the ligand-receptor 
interaction and receptor activation as well as the rate of the receptor internalization might 
play a role in the fate of the cell regarding the downstream signaling and functional 
outcomes. 
It was reported that the mitogenic potency of insulin analogs was inversely related 
to their dissociation rate from IR, while all analogs that had a slower off rate than insulin 
stimulated thymidine incorporation more than would be expected from their relative 
affinities. Moreover, the ability of negative cooperativity of these analogs also decreased as 
their mitogenic potency increased (122,213). It was also proposed that the mitogenic signal 
may be dependent on the strength of the interaction of the hormone with the receptor site 1, 
and that the negative cooperativity may act as a device that dampens mitogenic signaling 
by both insulin and IGF-1 (122,214).  
A model by Shymko et al. proposed that binding of the ligand to the receptor might 
activate the receptor to promote the accumulation of an activator at a characteristic rate, 
and signaling occurs only when the activator exceeds a threshold level. In case that the 
receptor remains activated by the ligand for a sufficient time, the threshold is attained and 
the corresponding signaling pathway is triggered. However, if the ligand dissociates and 
the receptor becomes deactivated before the threshold of the activator molecule is reached, 
there will be no signal at all, or an alternative pathway that was triggered at a lower 
threshold will be chosen (215).  
For all these reasons, it looks very probable that the time factor in the receptor 
activation plays a crucial role in the signaling of insulin and both IGFs. 
 
1.5 Insulin/IGF system in physiology and disease 
Deregulation of insulin/IGF system has been connected with many pathological 
states, including mainly metabolic disorders, such as diabetes and obesity, and growth 
disorders, but it is also involved in several types of malignant processes. 
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Diabetes mellitus is a state characterized by the inability of the organism to produce 
sufficient amounts of endogenous insulin (type 1 DM) or decreased sensitivity of 
peripheral tissues to the hormone (type 2 DM) (216). Both types of DM result in elevated 
plasma concentration of glucose. Long term exposure to elevated glucose concentration is 
connected with pathological states that include rethinopathy, nephropathy, neuropathy 
(217) as well as cardiovascular (218) and cerebrovascular disease (219).  
Aberrant production of IGF-1 is connected with growth disorders such as Laron 
syndrome (7) or acromegaly (8), but also with osteoporosis (38) and cardiovascular disease 
(220,221). It was also shown to play a role in the development of pathological states such 
as Alzheimer´s (222) or Huntington´s (223) disease. Moreover, a correlation has been 
found between elevated IGF-1 production and several types of cancer including breast 
(224,225), prostate (226,227), colorectal (228,229) or brain (230) cancer. Even though the 
establishment of autocrine and paracrine signaling loops seems to be the most common 
mechanism by which IGF-1 and its receptor are involved in cancer development (231), the 
upregulation of IGF-1R was also observed in several tumor types, including prostate 
colorectal, ovarian, breast or lung cancer as well as melanoma (232-235).  
Interestingly, in the last few decades, accumulating evidence has indicated that both 
IR isoforms may also play an important role in cancer development as they were found to 
be abnormally overexpressed in various types of cancer cells (235). In certain cancer types, 
IR may play even more important role than IGF-R (6). The IR-A:IR-B ratio seems to be a 
significant factor: it is generally increased in favor of IR-A in malignant cells.  
The increased IR-A:IR-B ratio was observed in breast (236,237), prostate (238), 
endometrial (239,240), lung (241) or hepatic (242)  cancer. Moreover, an increased risk for 
development of cancer was observed in diabetic patients exposed to both endogenous and 
exogenous hyperinsulinemia (16,243,244). All these findings indicate that both IGF-1R 
and IR (IR-A especially) should be taken into account when considering anti-cancer 
therapies. 
Regarding IGF-2, in addition to its role in the growth abnormalities such as 
Beckwith-Wiedemann syndrome and Silver-Russel syndrome (3,45), that were mentioned 
in chapter 1.1.1.2, there has been evidence that it can also promote tumor growth.  
In various studies, elevated levels of IGF-2 or its mRNA correlated positively with the 
development of brain (230,245), colon (246), liver (247), ovarian (248) or prostate (249) 
tumors. The term IGF-2-oma was introduced for large solid tumors either of mesenchymal 
or epithelial origins, which are known to overproduce IGF-2, resulting in further autocrine 
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and paracrine stimulation of the tumor cells (250). Last but not least, it is believed that 
IGF-2 disbalance could be involved in the development of cardiovascular disease (251). 
 
1.6 Insulin/IGF system and perspectives in therapy  
Due to the connection of the deregulation of the insulin/IGF system with diseases 
such as diabetes mellitus and cancer, that are subjects of scientific research worldwide, it is 
not surprising that there have been many attemtps to target the receptors of the system 
regarding anti-cancer and anti-diabetes therapy.  
There has been strong effort focused on targeting IGF-1R. In general, there have 
been two major approaches: to prevent the ligand binding by developing an antagonistic 
agent (252-255) or to inhibit the function of the receptor by targeting the TK domain 
(256,257). Unfortunately, the results of both of these approaches up to this date have been 
disappointing (254,258,259). Development of a specific IGF-1R TK domain inhibitor is 
challenging due to the high similarity with the TK domain of IR (84%) (73) as well as with 
other tyrosine kinases. Thus, the results of clinical trials have not been satisfactory because 
of the cross-reactivity of the drugs with IR and their toxicity (254,258,259). In the case of 
preventing the ligand binding, a strong attention was focused on anti IGF-1R antibodies 
(252,253,258,259). Although the results of preclinical studies were promising, the clinical 
results were disappointing as significant effects have been observed only in some relatively 
rare tumor types such as Ewing´s sarcoma, (260-262), sarcoma and adrenal cortical 
carcinoma (263) and some non-small cell lung carcinoma (264). However, the 
development of IGF-1R antagonist is still of great interest. Of course, besides the 
antibodies, a development of IGF-1 analog with antagonistic properties is another option, 
however, to date, no such antagonist have been identified.  
An IR-B specific analog would be of great interest regarding DM treatment. Such 
analog would better mimic the endogenous insulin fate in the body. Briefly, endogenous 
insulin, that is synthesized in pancreas, is secreted directly into the portal vein and passed 
to the liver. The liver contain predominantly the B isoform of IR and it is estimated that it 
clears up approximately 50% of the synthesized insulin, resulting in the suppression of 
glycogenolysis and gluconeogenesis, the major factors contributing to the decrease of 
plasma glucose levels. On the other hand, the subcutaneously adminestered insulins are 
extensively picked up by the peripheral tissues (69,265), which results in insufficient 
suppression of hepatic gluconeogenesis and glycogenolysis as well as in undesirable IR-A 
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stimualtion in extrahepatic tissues. It was shown that some insulin analogs that are used for 
DM treatment have increased mitogenic potencies (6,266-268). Therefore, the analog  that 
would be selective for IR-B could potentially increase the efficiency of the treatment of 
diabetes as well as minimize the side effects that may result in cancer.  
 
1.6.1 Insulin and IGF-1 mimetics 
Another option regarding the therapies targeting IR and IGF-1R would be insulin or 
IGF-1 mimetics – nonpeptide agonists or antagonist of the receptors, or peptide mimetics 
structurally nonrelated to the wildtype ligands. Potentially, these mimetics could be less 
expensive alternative to the analogs and they could also be  metabolically more stable, 
which could make them suitable for oral delivery. This could be beneficial especially for 
the insulin treated DM patients, as oral delivery of insulin and its analogs is impossible due 
to their instability in the digestive track (69,269). Moreover, it is believed that the oral 
derivery would better mimic the physological seretion to the portal vein (269). It was 
previously shown by Novo Nordisk  that the mimetic approach is promising as they 
discovered a group of peptides, unraleted to insulin, that bind to IR. Peptides with both 
agonistic and antagonistic behaviour have been identified (270,271). Moreover, it was 
shown that one of these peptides, named S597, has affinity comparable to insulin but 
stimulates predominantly the PI3K/Akt pathway (210). This raise also the possibility to 
design receptor mimetics that could selectively induce metabolic, but not mitogenic, 
pathways (210). However, all these peptides still have a similar molecular weight to insulin 
and similar stability (210,270,271). The achieved results are encouraging enough for 
search and design of new functional mimetics. 
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2 RESEARCH AIMS 
 
Aim 1 
The main aim of this work was to introduce the methodology and test the broad 
spectrum of insulin, IGF-1 and IGF-2 analogs and insulin mimetics produced in our 
laboratory for the ability to activate IR-A, IR-B and IGF-1R and the two downstream 
signaling pathways (PI3K/Akt and Ras/MAPK). The groups of analogs and mimetics 
tested that are included in this thesis are: 
 insulin-IGF-1/IGF-2 hybrid analogs containing the A and B chains  
of insulin and the C or D domains derived from IGF-1 or IGF-2 or their 
parts 
 IGF-1 and IGF-2 analogs with mutations in the positions 45, 46 and 49 
(IGF-1) and 45 and 48 (IGF-2) 
 libraries of nonpeptide trifunctional scaffold-derived compounds 
 
 
Aim 2 
During the testing of other analogs, an insulin analog with suprisingly high ability 
to activate the IGF-1R ([D-HisB24]-insulin) was identified. Therefore, a second aim of the 
work arose: 
 to prepare a new set of insulin analogs that could help to explain this 
behaviour 
 to test the binding affinities of the newly prepared analogs for IR-A, IR-B 
and IGF-1R and their abilities to activate the receptors  
 to customize methodology for kinetic assays (association and dissociation 
kinetics, negative cooperativity) and characterize the kinetics of IR-A  
and IGF-1R binding of [D-HisB24, GlyB31, TyrB32]-insulin, that was 
found to be even more potent binder and activator of IGF-1R than  
[D-HisB24]-insulin 
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3.1 A Versatile Insulin Analog With High Potency for Both Insulin and Insulin-Like 
Growth Factor 1 Receptors: Structural Implications for Receptor Binding 
 
Background 
Insulin and IGF-1 are closely related hormones involved in the regulation of 
metabolism and body growth. They elicit their functions through activation of tyrosine 
kinase-type receptors: two isoforms of insulin receptor (IR-A and IR-B) and IGF-1R. 
Despite structural similarities of both the ligands and the receptors, insulin and IGF-1 bind 
the non-cognate receptor with substantially reduced affinity. The structural determinants 
responsible for this behaviour are still not completely understood. The commonly accepted 
assumption is that the hormones interact with two distinct binding sites on the receptor 
(Site 1 and Site 2). The Sites 1 of IR and IGF-1R and their modes of interaction with the 
hormones were shown to be similar (103,110,114). However, the exact nature of the Sites 
2 remains not completely resolved. Site 2 is believed to be a significant factor responsible 
for the receptor specificity.  
In course of routine testing of analogs prepared in our laboratory, we detected an 
unexpectedly high binding and stimulation of IGF-1R by [D-HisB24]-insulin (affinity 
increased 13 times compared to insulin). A work published previously by our laboratory 
(141) showed that the reverse chirality in the position B24 resulted in a B25→B24 
downshift and subsequent downshift of the following aminoacids in the C-terminus of the 
B chain. We designed, prepared and tested a new set of analogs with the aim to test a 
hypothesis that the structural change of [D-HisB24]-insulin might somehow result in 
mimicking of IGF-1-like binding.  
 
Summary of the results 
We prepared six new analogs with the changes in the C-terminus of insulin B chain 
using enzymatic semisynthesis. These analogs holded sequences providing the downshift 
observed in the [D-HisB24]-insulin as well as sequences derived from the part of IGF-1 
analogous to the C-terminal part of insulin B chain. We measured binding affinities and 
receptor activation of these analogs for IR-A, IR-B and IGF-1R. The results excluded our 
hypothesis that the structural downshift results in an IGF-1-like behaviour. However, we 
found that [D-HisB24, GlyB31, TyrB32]-insulin, which combines the presence of the  
D-histidine in position B24 with the prolongation of the segment by two additional 
 54 
aminoacids derived from IGF-1, is even stronger binder of IGF-1R as its affinity is 
increased 150 times compared to insulin. This analog binds also IR-A and IR-B with 
increased affinity and the abilities to activate the receptors follow the trends of binding. 
We measured association and dissociation rate of the analog for IR-A and IGF-1R to shed 
more light onto the character of the interaction. We observed that while decreased 
dissociation rate is responsible for the increased affinity for IR, increased association rate 
is responsible for the increased affinity for IGF-1R. 
We assumed that the structural changes allow the directing of the C-terminus of 
insulin B chain to some extra interaction with the receptors and that these unusual 
interactions lead to a decrease of dissociation rate from IR and conversely enable easier 
association with IGF-1R. Because all the modifications of the analog were made in the 
area which is thought to interact with the Site 1 of the receptors, the results suggest that 
merely modifications affecting the interactions with Site 1 are sufficient to change the 
receptor specificity of insulin. 
 
My contribution 
I prepared all the six new analogs described in the paper. I measured the abilities to 
stimulate the receptors and I participated in measuring of the binding affinities.  
I customized the protocol for kinetic assays and measured all the kinetic properties.  
I contributed to the preparation of the manuscript. 
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3.2 Insulin-Insulin-like Growth Factors Hybrids as Molecular Probes of 
hormone:Receptor Binding Specificity 
 
Background 
Insulin, IGF-1 and IGF-2 and their receptors (IR-A, IR-B and IGF-1R) are key 
elements of a complex hormonal system that is essential for development and functioning 
of mammals. Insulin and IGF-1 bind preferentially to their cognate receptors. IGF-2 binds 
to both IGF-1R and IR-A with relatively high affinity (66). The C and D domains of IGF-1 
and IGF-2 do not have any analogous counterpart in the structure of insulin and thus they 
represent the major structural differences between insulin and IGFs. The functional impact 
of the C and D domains of IGFs is still not completely understood. It is envisaged, 
however, that they play some role in the differential binding of IGF-1 and IGF-2 to IR-A, 
IR-B and IGF-R as well as in the activation of the receptors (67,272). 
Here, we attempted to probe the impact of IGF-1 and IGF-2 D domains and IGF-2 
C domain on the receptor specificity by preparation and characterization of insulin-IGF 
hybrid analogs.  
 
Summary of the results 
Seven new insulin hybrid analogs were prepared within this study. The first group 
contained an extension by amino acids derived from the D domains of IGF-1 and IGF-2 at 
the C-terminus of insulin A chain (3 analogs). The second group contained an extension by 
aminoacids mimicking the beginning of the C domain of IGF-2 at the C-terminus of insulin 
B chain (4 analogs). The binding affinities and abilities to activate IR-A, IR-B and IGF-1R 
were characterized.  
It was shown that the D domain of IGF-1 had more negative impact on binding to 
IR than the D domain of IGF-2. The addition of the whole IGF-2 D domain diminished 
more the affinity to IR-B (53% compared to native insulin) than to IR-A (85%). There 
were no significant differences in the ability to activate the receptor compared to binding. 
The results also indicate that the addition of amino acids mimicking the beginning 
of the IGF-2 C domain to the C-terminus of insulin B chain change the binding and 
autophosphorylation specificity of the analog in favor of the „matabolic“ IR-B. While the 
affinities of three of the four prepared analogs for IR-B were similar or slightly higher 
compared to insulin, the ability to activate this receptor was increased 2-3 times in three 
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cases. In case of IR-A, the binding affinities of all four analogs as well as their abilities to 
activate the receptor were similar or decreased compared to insulin. This could open a new 
path into the design and preparation of novel insulin analogs with enhanced IR-B 
specificity, that would be beneficial for clinical applications. 
Although it was expected that the addition of the C and D domains of IGFs to the 
molecule of insulin would increase the affinity of the analogs for IGF-1R, all analogs 
exhibited very low binding affinities for the receptor, which were comparable to insulin. 
Similarly, also the abilities of the analogs to activate IGF-1R were comparable to insulin. 
 
My contribution 
I participated in the measurment and evaluation of binding affinities of the analogs 
to the receptors and their abilities to activate the receptors.   
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3.3 Converting Insulin-like Growth Factors 1 and 2 into High-Affinity Ligands for 
Insulin Receptor Isoform A by the Introduction of an Evolutionarily Divergent 
Mutation 
 
Background 
IGF-1 and IGF-2 are protein hormones involved not only in normal growth and 
development, but also in life span regulation and cancer. They exert their function mainly 
through the IGF-1R and the “mitogenic“ isoform of IR (IR-A). The development of IGF-1 
and IGF-2 antagonist is of great clinical interest, however, to date, no IGF-like peptide 
antagonist of the IGF-1R has been identified and the results of clinical trials of other types 
of antagonists in recent years were not satisfactory (254,258,259). Therefore, a selective 
IGF-like antagonist of the IGF-1R could provide a promising new strategy for combating 
IGF-1R related malignancies.  
A previous work on insulin showed that mutations of positions GluA4 and ThrA8 
by His lead to analogs with native IR binding affinity, but impaired ability to activate the 
receptor and stimulate downstream signaling (273). This inspired us to systematically 
modify residues Asp45, Glu46 and Phe49 in IGF-1 and residues Glu45 and Phe48 in  
IGF-2, which correspond, or are close, to insulin sites A4 and A8, and test whether such 
mutations can generate significant IGF-1R antagonists. 
 
Summary of the results 
A series of eleven IGF-1 and three IGF-2 analogs mutated at the sites 45, 46 and 49 
in the molecule of IGF-1 and 45 and 48 in the molecule of IGF-2 was prepared. Their 
binding affinities for IGF-1R and IR-A and abilities to activate these receptors were 
determined. No major discrepancies between IGF-1R binding and activation properties of 
the analogs were observed. However, we observed that the presence of His49 and His48 in 
IGF-1 and IGF-2, respectively, enhances the binding affinity for IR-A. The affinity of all 
four IGF-1 analogs containing Phe49His mutation was increased 4-9 times compared to 
native IGF-1. These analogs, however, did not show any antagonism as their capabilities to 
activate IR-A were superior or similar to those of native IGF-1. Similarly to IGF-1 analogs, 
the Phe48His mutations in IGF-2 lead to 5-7 fold increase in the IR-A affinity. Both  two 
IGF-2 analogs carrying this mutation, that were prepared within this study, bind IR-A with 
subnanomolar affinities, which make them half-equipotent to human insulin with respect to 
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this IR isoform. The IR-A activation abilities of these two IGF-2 analogs are also very 
high, with a potency similar to that of native insulin. These results prompted us to test the 
binding affinities of chosen analogs for the “metabolic” isoform of IR (IR-B) as well. 
Interestingly, the affinities of theese analogs for IR-B were also significantly increased in 
comparison to the wildtype IGFs. 
To the best of our knowledge, the analogs prepared within this study, that carry the 
His mutation in the position 49 (IGF-1) or 48 (IGF-2) are the strongest IGF-1-like and 
IGF-2-like binders of IR thus far reported. Despite any of the analogs studied here have not 
shown clear antagonistic properties, it was revealed that new IGF-1 and IGF-2 mutants can 
interact differently with the receptors for insulin and IGF-1. This could indicate new 
directions for a rational engineering of these hormones. 
 
My contribution 
I participated in the measurment of binding affinities of the analogs to the receptors 
and their abilities to activate the receptors.  I contributed to the preparation of the 
manuscript. 
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3.4 Synthesis and Evaluation of a Library of Tri-Functional Scaffold-Derived 
Compounds as Modulators of the Insulin Receptor 
 
Background 
Considering the central position of insulin in antidiabetes therapy, there is a need 
for alternative forms of this hormone that would be metabolically stable (suitable for oral 
delivery) and less expensive to produce than insulin. Therefore, nonpeptide molecules 
(insulin mimetics) that would be able to bind IR efficiently and elicit the metabolic 
responses of native insulin, would be of major interest. In a previous work of our 
laboratory, a versatile trifunctional scaffold with orthogonally protected arms that can be 
selectively functionalized by different azides was developed (274). In this study, we aimed 
to prepare a library of nonpeptide compounds based on the scaffold, that would mimic 
insulin binding epitopes. We used the combinatorial approach and tested the libraries for 
biological activity regarding IR-A and IGF-1R. 
 
Summary of the results 
A combinatorial library of 1000 compounds based on the scaffold from our 
previous work (274) was synthesized. For this purpose, a pool of 30 azides with various 
chemical properties was prepared. The original library contained 10 sublibraries, where 
each of them contained 100 different compounds. Every compound in the library contained 
three different azides at the three arms of the trifunctional scaffold. The sublibraries were 
tested for binding to IR-A and IGF-1R and their abilities to activate these receptors. Based 
on the results of the biological assays, chosen sublibraries were deconvoluted to smaller 
sublibraries (10 x 10 compounds and  then 10 x 1 compounds). Two compounds which 
were able to weakly bind to IR-A and induce its activation were identidied. Despite the 
modest biological resutls, this study enabled us to test our synthetic and biological 
methodology and to prove its robustness and reliability. It represents a unique example of 
targeting the IR with a set of nonpeptide compounds that were specifically designed and 
synthesized for this purpose. 
 
My contribution 
I participated in the measurment of the abilities of the scaffold-based libraries and 
compounds to activate the receptors. 
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4 RESULTS AND DISCUSSION 
4.1 Testing of the signaling properties of analogs and mimetics produced in our 
laboratory 
The main aim of this work was to develop a reliable methodology for testing of the 
signaling properties of the insulin, IGF-1 and IGF-2 analogs and insulin mimetics 
produced in our laboratory. It was intended to measure the activation of IR-A, IR-B and 
IGF-1R and the ability to trigger the PI3K/Akt and Ras/MAPK signaling pathways after 
stimulation of the individual receptors. 
The activation of the receptors as well as the activation of proteins Akt and Erk, 
which are commonly used representatives for measurement of the two signaling pathways 
(208,275-277), comprise phosphorylation of specific residues within the proteins 
(161,162,278-280). Specific antibodies detecting the phosphorylated form of all these 
proteins are comercially well available. Therefore, a standard immunobloting methodology 
was incorporated into the testing.  
However, the natural cells and most established cell lines usually express mixtures 
of IR-A, IR-B and IGF-1R in various ratios. To enable testing the characteristics of each 
receptor separately we acquired specially developed cell lines, that were kindly donated  
by Prof. Antonino Belfiore (University of Catanzaro, Italy). Mouse embryonic fibroblasts, 
that naturally carry IGF-1R, were knocked out for mouse IGF-1R and transfected either 
with human IR-A (R-/IR-A cells), IR-B (R-/IR-B cells) or IGF-1R (R+39) cells. These cell 
lines express the receptor of interest in high amount, which is convenient because 
stimulation with a ligand provides strong and easily detectable signal.  
Next step in the establishment of the methodology was to standartize the conditions 
for the stimulation of the cells. Finally we implemented a procedure allowing us to test and 
compare series of analogs. The standard methodology comprises stimulation of the cells by 
a ligand at 10 nM concentrations for 10 min. At this concentration we get maximal 
response induced by the native ligand and it allows us to make relevant qualitative 
conclusions about general antagonism or agonism of analogs. The methodology was first 
published in the study of Křížková et al. (81). Within the time, we also implemented 
methodology for an in-cell western, which enables us to test the dose-response curves more 
conveniently compared to the classical western blotting. This methodology was first 
published in the study of Macháčková et al. (281).  
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During the testing of several series of analogs, we have repeatedly observed 
disproportion of binding affinities versus the potency to activate the receptors and the 
intracellular proteins Akt and Erk. Specifically, when a ligand is a strong binder of a 
receptor, the signal is not adequately reflected in the increase of the activation of the 
proteins. Conversely, a weak ligand can induce a relatively strong signal. This is probably 
because the cells are not “equipped” enough with an intracellular signaling machinery for 
the amount of signaling that they receive from the high number of transfected receptors. 
The system gets easily saturated and the cells do not have enough kinases and 
phosphatases to translate or extinguish the signal.  
Although the binding and signaling are not truly proportional, the trends of patterns 
observed for receptor activation are in accord and satisfactory for the purposes of basic 
characterization of receptor activation potency of the tested analogs. Using our 
methodology, we would be able to search for larger disproportions, e.g. to be able to detect 
a ligand exerting significant selectivity towards one kind of the receptor or to recognize a 
receptor antagonist. Unfortunately, in case of the intracellular proteins Akt and Erk, the 
disproportions were getting more significant. The differences between strong and weak 
binders were getting smaller while detecting the activation of these proteins, which 
obviously did not reflect the real signaling properties of the ligands. We showed in a 
publication that is not included in this thesis (281) by stimulation of non transfected 
NIH/3T3 fibroblasts (that carry the mouse IGF-1R) that in a more natural cell model, the 
pattern of Akt activation follows the receptor activation and the binding affinities. 
A use of cell lines that carry a natural number of receptors on the cell surface might 
seem to be more beneficious here, however, as was already mentioned, natural cell lines 
carrying exclusively one of the three types of the receptors are rare and the lower amount 
of receptors would also bring complications with the signal detectability. For all these 
reasons, we take the advantage of the system of our transfected cell lines. Even though we 
routinely test the autophosphorylation of the receptor as well as the phosphorylation of 
proteins Akt and Erk, which serve us for control of the signaling patterns, we regularly use 
only the receptor activation data for publication purposes.  
To summarize, during the period of my working in the laboratory, following 
methodologies were implemented and standardized: 1) the standard western blot 
methodology for testing of the signaling properties of series of analogs and other 
compounds, 2) in-cell western and also 3) kinetic assays, that will be discussed  
in chapter 4.2. 
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4.2 Insulin analogs with high potency to activate IGF-1R: synthesis, signaling and 
kinetic characterization 
Insulin and IGF-1 are closely related hormones that elicit their function through 
activaion of IR and IGF-1R. Despite structural similarities of both the ligands and the 
receptors, insulin and IGF-1 bind the non-congate receptor with substantially reduced 
affinity. The structural determinants responsible for this behaviour are still not completely 
understood. In course of routine testing of analogs prepared in our laboratory, we detected 
an unexpectedly high binding and activation of IGF-1R by [D-HisB24]-insulin (affinity 
increased 13 times compared to insulin). A work published previously by our laboratory 
(141) showed that the reverse chirality in the position B24 resulted in a B25→B24 
downshift and subsequent downshift of the following aminoacids in the C-terminus of the 
B chain. Based on the comparison of the structures of the analog and native insulin and 
IGF-1 (see figure 12), we hypothesized that the structural downshift in the C-terminus of 
the B chain of the analog could somehow result in mimicking of IGF-1-like binding. 
Therefore, we designed, prepared and tested a new set of analogs with the aim to test this 
hypothesis. 
 
 
 
 
 
 
 
 
 
Figure 12: An overlay of the B chains/ B domain of human insulin, human IGF-1 and  
[D-HisB24]-insulin. Insulin (PDB code 1MSO, crystal structure) is in grey, IGF-1 (PDB 
code 1GZR, crystal structure) is in ocher and [D-HisB24]-insulin (PDB code 2M2P, NMR 
structure with the lowest energy at pH 8) is in red. The critical aminoacids in the C-
terminus are indicated(4).  
 
Six new insulin analogs with the changes in the C-terminus of the B chain were 
successfully prepared using enzymatic semisythesis. These analogs holded sequences 
mimicking the downshift observed in the [D-HisB24]-insulin as well as sequences derived 
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from the corresponding part of IGF-1. All the analogs prepared within this study are 
schematically shown in figure 13.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Schematic representation of analogs prepared within this study and  
a comparison of the aminoacid composition of their B chain C-terminal parts with 
IGF-1 and insulin. Single letter codes of aminoacids are used. DOI is des-(B23-B30)-
octapeptide insulin. The expected downshift of the B25 residue and the residues upward 
due to the presence of D-His in the B24 site is indicated by bending of the connecting line 
(4). 
 
The binding affinities and abilities to stimulate IGF-1R as well as both isoforms of 
IR were charecterized. Our original hypothesis that the structural downshift results in an 
IGF-1R-like behaviour was rather excluded, as the [TyrB25, PheB26, AsnB27, LysB28, 
ProB29]-insulin, which bears the C-terminal sequence of the IGF-1 B domain, had IGF-1R 
affinity similar to insulin. Nevertheless, we found that [D-HisB24, GlyB31,  
TyrB32]-insulin, which combines the presence of the D-His in position B24 with the 
prolongation of the segment by two additional aminoacids derived from IGF-1, is even 
stronger binder of IGF-1R than [D-HisB24]-insulin. The affinity of this analog to IGF-1R 
increased 150 times compared to insulin, which made it comparable to IGF-2 and 
significantly more potent than the well-known “supermitogenic” [AspB10]-insulin (known 
as analog X10) and [ArgB31, ArgB32]-insulin (affinities to IGF-1R increased ~5 times 
and ~30 times  compared to insulin, respectively) (266,282,283). The increased affinity 
was accompanied by significantly increased receptor activation as well. To the best of our 
knowledge, the [D-HisB24, GlyB31, TyrB32]-insulin is one of the strongest insulin-like 
binders and activators of IGF-1R ever reported.  
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Surprisingly, the addition of GlyB31 and TyrB32 to the [D-HisB24]-insulin also 
improved binding to IR-A (251% vs 204% compared to insulin) and even more profoundly 
to IR-B (338% vs 183%).  In general, all the analogs with the B chain C-terminus extended 
by GlyB31 and TyrB32 showed increased IR binding in comparison with their counterparts 
without these two aminoacids as well as with native insulin, and an increased IR-B/IR-A 
ratio was observed for these analogs. We did not detect any deviations in the abilities of 
the analogs to stimulate IR-A and IR-B compared with insulin. 
To obtain a closer insight into the binding characteristics of the [D-HisB24, 
GlyB31, TyrB32]-insulin, which was shown to be a versatile binder of the three receptors 
belonging to the insulin/IGF system, we performed measurements of association and 
dissociation kinetics and also the dose response curves for accelerated dissociation  
(the ability of the negative cooperativity) of this analog, insulin and IGF-1 toward IR-A 
and IGF-1R. For this purpose, we needed floating cell lines as the experiments require 
large dilution that is difficult to obtain on culture plates, and also rapid separation of bound 
and free ligand (284). For testing on IR-A, we used IM-9 cell line, which is available in our 
laboratory. However, there was not any suitable floating cell line expressing solely IGF-1R 
available. Therefore, we used the advantage of CHO-K1 cell line, which is useful for 
transfection experiments and it was shown previously that it is possible to maintain this 
cell line in floating culture for a sufficient period of time and to use it for the kinetic 
experiments (284). The CHO-K1 cell line expresses certain level of hamster IGF-1R. We 
did not find detectable levels of IR on immunoblots. Upon transfection with human  
IGF-1R gene we obtained a new stable cell line with about ten times enhanced expression 
of human IGF-1R compared to the hamster one, making this cell line suitable for our 
experiments. 
The results of the dose response curves for accelerated dissociation were consistend 
with previous observations. It was shown previously that IR and IGF-1R differ in this 
regard, as the dose response curve for accelerated dissociation for IR is bell-shaped, 
whereas the curve for IGF-1R is sigmoid (103,120,122,152-156). Our results supported the 
indications that the different curves are reflecting different properties of the receptors 
rather than analogs.  
However, the results of association and dissociation kinetics brought new insight 
into the surprising behaviour of [D-HisB24, GlyB31, TyrB32]-insulin. To interpret the 
data, we employed presumtions formulated in a mathematical model of harmonic oscilator, 
which is used to describe the binding kinetics of insulin and IGF-1 to their receptors 
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(103,285). We observed that in case of IR-A, the association rate of the analog is 
comparable to insulin, whereas its dissociation rate is about three times lower compared to 
insulin. The dissociation kinetics would probably be an even more distinguishing factor for 
IR-B affinity. Conversely to IR-A, the association rate of the [D-HisB24, GlyB31, 
TyrB32]-insulin on IGF-1R was about 20 times increased compared to insulin, while the 
dissociation rate of the analog was comparable to isnulin. We found that while the 
dissociation kinetics seems to be the major factor responsible for the increased IR affinity 
of the analog, the association kinetics seems to be the major factor responsible for the 
inreased affintity to IGF-1R. 
Because all the changes in [D-HisB24, GlyB31, TyrB32]-insulin are made in the 
area hormone Site 1 (see chapter 1.3.1 in Introduction), we showed by our results that 
modifications in the Site 1 interactions are sufficient for significant changes in receptor 
specificity. This is quite surprising, as the Site 1 interactions of insulin and IGF-1 with 
their receptors were shown to be similar (103,110,114), and thus Site 2 interactions are 
generally believed to be responsible for the specificity. The only differences in the 
hormones´ Site 1 are TyrB16 and SerB9 in insulin, which are replaced with Gln15 and 
Ala8 in IGF-1, respectively, and Met59 in IGF-1, that does not have equivalent receptor-
binding residue in insulin. Ala8 in IGF-1 was shown to interact with both the L1 domain 
and αCT peptide of IGF-1R, whereas insulin SerB9 interacts only with IR αCT peptide 
(103,124). Insulin TyrB16 interacts with Phe39 of IR L1 domain, which corresponds to 
Ser35 in IGF-1R, which is not involved in ligand binding (104,124). We hypothesize that 
the lack of interactions provided by TyrB16 in insulin prevents anchoring of insulin on 
IGF-1R and accordingly slows down the association. We speculate that the relaxation of 
the C-terminus of the B chain, which is a consequence of the D-His presence, as shown by 
NMR studies, and the addition GlyB31 and TyrB32 in the [D-HisB24, GlyB31,  
TyrB32]-insulin, provide additional contacts with the receptor, not necessarily the same as 
in IGF-1, and partially compensate for the missing anchor.  
Based on the course of binding properties of insulin, IGF-1 and [D-HisB24, 
GlyB31, TyrB32]-insulin to IR and IGF-1R, we offer insight into the factors contributing 
to the selectivity to the receptors.  
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4.3 Signaling properties of insulin-IGF-1/IGF-2 hybrid analogs 
The C and D domains of IGF-1 and IGF-2 represent the major structural differences 
between the two chain insulin and one chain IGFs. The C domain is inserted between the  
A and B domains, whereas the D domain extends the C-terminus of the A domain  
(see figure 2 in Introduction (page 24)). It was proposed and supported by research 
(67,130,131,272,286) that the C and D domains play important roles in the differential 
binding of the IGFs to IR-A, IR-B and IGF-1R. Nevertheless, the reports regarding the  
C and D domains of IGF-1 and IGF-2 are infrequent and their functional impact is not well 
understood. Especially the understanding of the role of the IGF-2 C domain in receptor 
selectivity is still limited. Moreover, initial studies of insulin:D domain hybrids were 
reported in the 1980s and although they provide valuable data, insight into the binding 
affinities for the individual IR isoforms and IGF-1R was not gained at that time 
(130,287,288).  
This inspired us to elucidate the roles of the D domains of IGF-1 and IGF-2 and the 
C domain of IGF-2. Within this study, seven new insulin hybrid analogs were prepared and 
their binding affinities and abilities to activate IR-A, IR-B and IGF-1R were characterized. 
Three analogs contained an extension by amino acids derived from the D domains of  
IGF-1 and IGF-2 at the C-terminus of insulin A chain, whereas 4 analogs contained  
an extension by aminoacids mimicking the beginning of the C domain of IGF-2 at the  
C-terminus of insulin B chain (see figure 14). The sequences mimicking the IGF-2  
C domain were designed with respect to the methodological barrier in the synthesis (81).  
 
 
 
 
 
 
 
 
Figure 14: Schematic representation of analogs prepared within this study. Single 
letter codes of aminoacids are used. 1 and 2: IGF-1 D domain analogs, 3: IGF-2 D domain 
analog, 4-7: IGF-2 C domain analogs (81). 
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4.3.1 Impact of the sequences derived from the D domains of IGF-1 and IGF-2 on 
binding and activation of IR-A and IR-B 
The introduction of the D domain of IGF-1 to the molecule of insulin diminished 
the affinity to both IR isoforms to 25-30% compared to insulin. This result is consistent 
with previous observations that proposed unfarovable interference of the IGF-1 D domain 
with binding to IR (67,130,272,288). Our study showed that not the lenght of the IGF-1  
D domain, but in particular its first three aminoacids (Pro-Leu-Lys) are determining factor 
for the different IR affinities of IGF-1 and IGF-2. The impact of the D domain of IGF-2 
was less profound, as the affinity to IR-B was decreased only to 53% and the affinity  
to IR-A reached 85%. The only difference between the two IR isoforms are the 12 
aminoacids that are, due to alternative splicing of the IR gene exon 11, present in the  
C-terminal part of the α subunit of IR-B but not IR-A (64).Therefore, some specific and 
unfavorable interaction of the IGF-2 D domain with this segment could be behind  
the lower affinity of IGF-2 to IR-B than to IR-A. The abilities of these analogs to trigger 
the autophosphorylation of IR-A followed the basic trends of binding.  
The results indicate that the D domains of IGFs may be at least partly responsible 
for the higher affinity of IGF-2 to IR compared to IGF-1 as well as for the lower affinity  
of IGF-2 to IR-B than to IR-A. 
 
4.3.2 Impact of the sequences mimicking the C domain of IGF-2 on binding and 
activation of IR-A and IR-B 
The insulin analogs prepared with the aim to study the impact of the IGF-2  
D domain contained one to four aminoacids derived from the N-terminal part of this 
domain (see figure 14). The arginine within the sequence was substituted for lysine for 
synthetic reasons (81). 
The results of binding and activation of IR were quite surprising. In case of IR-A, 
the addition of the segments lowered their affinity to 43-88% of native insulin. However, 
in case of IR-B, the affinity of the analogs was similar or even increased compared to 
insulin (110-149%), with the only exception, which was the analog carrying two additional 
aminoacids (Ser-Lys), whose affinity for both IR-B and IR-A decreased. The lower affinity 
of this analog to IR could be caused by a negative effect of the C-terminal LysB32. This 
effect would be similar to the impact of the C-terminal arginine residues in the comercially 
used insulin glargine (266,289).  
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The abilities of the C domain hybrid insulin analogs to activate IR-A followed their 
binding trends. However, in case of IR-B activation, the analogs showed significantly 
higher (2-3 times) ability to activate to receptor compared to insulin. There has been 
evidence that modifications of the C-terminal part of insulin B chain can lead to increased 
specificity for IR-B (151,290,291). The exact position of the 12 IR-B extra aminoacids in 
the 3D structure of the receptor is still unknown. However, based on the structures of 
insulin cocrystalised with IR-A construct (110,151), a direct interaction of the C-terminal 
part of insulin B chain with these residues cannot be excluded. Therefore, our results 
underline the importance of the C-terminal part of insulin B chain for achieving IR-B 
specificity of the hormones.  
 
4.3.3 Impact of the sequences derived from the D domains of IGF-1 and IGF-2 and 
the C domain of IGF-2 on binding and activation of IGF-1R 
Although it could be expected that the introduction of the aminoacids derived from 
the C and D domains of IGFs to the molecule of insulin would enhance the binding  
to IGF-1R, this was not the case. Only the affinity of the analog carrying the IGF-2 D 
domain was significantnly increased compared to insulin (235%). In all other cases, the 
affinity was comparable to insulin or even lower and also the ability to activate the IGF-1R 
of all analogs was comparable to insulin. This is surprising especially in the case of 
addition of the IGF-1 D domain. It was observed before that the introduction of the IGF-1 
D domain to IGF-2 enhanced the affinity to IGF-1R three times (67). Therefore, it is 
possible that the role of the IGF-1 D domain in binding to IGF-1R differs in the context of 
insulin and IGF molecules.  
 
4.4 Binding and signaling properties of IGF analogs with mutations in positions 45, 46 
and 49 (IGF-1) and 45 and 48 (IGF-2) 
Broad evidence supported the involvement of IGF-1 and IGF-2, as well as their 
receptors (IGF-1R and to a lesser extent also IR-A) in cancer development (224-230, 
232-242). Therefore, to develop an IGF based receptor antagonist should represent a 
promising new strategy for combating IGF-1R related malignancies. Up to this date, there 
has not been any IGF-like peptide antagonist of the IGF-1R identified.   
It was shown previously by Whittaker et al. that in insulin, a combination  
of GluA4His and ThrA8His mutations leaded to an analog with full bindig potency to IR, 
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but decreased the ability to trigger the autophosphorylation of the receptor (273).  
The acidic character of GluA4 in insulin is preserved by Asp45 and Glu44 in IGF-1 and 
IGF-2, respectively. However, neutral GlnA5 in insulin is replaced by acidic Glu46 and 
Glu45 in corresponding sites in IGF-1 and IGF-2 (see figure 15). These observations 
prompted us to study whether mutations of these residues in IGFs would have impact on 
binding affinities to IGF-1R and IR-A and whether such mutations could generate an IGF-
1R specific antagonist. Some of these mutations were also combined with Phe49His 
mutation in IGF-1 and Phe48His mutation in IGF-2, as it was shown that the 
corresponding ThrA8His mutation in insulin significantly contributed to the antagonistic 
properties of the mentioned analog (273).  
 
 
 
 
 
 
 
 
 
Figure 15: Comparison of the primary sequences of human insulin, IGF-1 and IGF-2 
with the sites mutated in this study highlited. Single letter codes of aminoacids are used. 
The organization of the B, C, A and D domains (B and A chains in insulin) is shown below 
the sequences. The homologous regions are highlited in grey and the residues mutated in 
this study are highlited in yellow (292).    
 
A series of eleven IGF-1 analogs with one, two or three mutations within the sites 
45, 46 and 49, and three IGF-2 analogs with one or two mutations within the sites 45 and 
48 were prepared. Unfortunately, no IGF-2 analog with the mutation in the position 44 was 
succesfully prepared in sufficient amount. The binding affinities of the prepared analogs  
to IGF-1R and IR-A and their ability to activate the receptors were determined. 
 
4.4.1 Impact of the mutations in positions 45, 46 and 49 (IGF-1) and 45 and 48  
(IGF-2) to IGF-1R binding and activation 
Unfortunately, no analog with clear IGF-1R antagonistic properties was found. 
Even though in case of IGF-1 analogs with mutations in the position 46 ([His46]-IGF-1 
and [Gln46]-IGF-1), slightly increased binding affinity to IGF-1R (in both cases 133% 
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compared to IGF-1) was followed by slightly decreased potency to activate the receptor 
(~70% in both cases), these differences were not statistically significant. In general, the 
mutations did not dramatically alter the binding affinities for IGF-1R and their abilities to 
activate the receptor in comparison to native IGFs. Therefore, the previously observed 
disproportionate binding and receptor activation of the insulin analogs mutated at sites A4 
and A8 (273) are probably specific and limited to insulin:IR interaction.  
 
4.4.2 Impact of the mutations in positions 45, 46 and 49 (IGF-1) and 45 and 48  
(IGF-2) to IR binding and activation 
The results of IR-A binding and activation were rather surprising as it was shown 
that the presence of His49 in IGF-1 as well as His48 in IGF-2 enhances the affinity to this 
receptor. The affinity of IGF-1 analogs carrying this mutation was increased 4 – 9 times 
compared to IGF-1 and the affinity of IGF-2 analogs was increased 5 – 7 times compared 
to IGF-2 (approximating 50% affinity of insulin). This effect was translated also to the 
receptor activation, as the capability to activate IR-A of the IGF-1 analogs was superior or 
similar to native IGF-1, and the IGF-2 analogs stimulated the receptor with potency similar 
to insulin. This outstanding enhancement of IR-A binding and activation prompted us to 
study the properties of representative analogs towards IR-B as well. Most interestingly, we 
found that this mutation significantly increased the affinity and ability to stimulate IR-B, 
too. To the best of our knowledge, the IGF-1 and IGF-2 analogs with the mutations in 
positions 49 and 48, respectively, are the strongest IGF-like binders of IR ever reported. 
The different effects of these mutations on binding affinities to IR and IGF-1R may 
indicate that the aminoacids at these sites are engaged with significantly different protein 
environments in complexes with IR and IGF-1R.  
 
4.5 Signaling properties of nonpeptide trifunctional scaffold-derived compounds 
Nonpeptide insulin mimetics could provide an elegant approach leading to an 
alternative forms of this hormone that would be metabolically stable (suitable for oral 
delivery) and less expensive to produce than insulin. Up to this date, there have been only  
a few reports on the development of nonpeptide insulin mimetics (293-297).  
In a previous work of our laboratory, a versatile trifunctional scaffold with 
orthogonally protected arms that can be selectively functionalized by different azides was 
developed (274). The design of the scaffold was motivated by insulin binding to IR  
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(see figure 16). In the current study, a pool of 30 azides with various chemical properties 
was prepared. A combinatorial library of 1000 compounds based on the scaffold from our 
previous work was sytnthetised.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Schematic representation of the development of insulin mimetics.   
A: The molecular surface of active (receptor bound) conformation of insulin represented 
here by the crystal sctructure of AsnB26 insulin (PDB code 4UNG). Examples of selected  
IR binding epitopes are highlited in yellow, green and blue. B: The respective aminoacids 
of the selected IR binding epitopes of insulin. C: The trifunctional scaffold (274) was 
designed to mimick the selected IR binding epitopes of insulin (298).  
 
The original library contained 10 sublibraries (C1 – C10), where each of them 
contained 100 different compounds. Every compound in the library contained three 
different azides at the three arms of the trifunctional scaffold. The sublibraries were tested 
for binding to IR-A and IGF-1R and their abilities to activate these receptors. Only two 
sublibraries (C2 and C4) significantly activated IR-A over the background level at the 
concentration 0.1 mM. However, the degree of receptor autophosphorylation was much 
lower (~10%) than the activation induced by 10 nM native insulin. Moreover, it was not 
convicingly accompanied by the inhibition of insulin binding to IR-A. These results could 
indicate that the compounds bind to another site on IR compared to insulin.  
The sublibrary C4 was deconvoluted to 10 smaller sublibraries, where each of them 
contained 10 different compounds. However, none of these mixtures activated IR-A nor 
inhibited insulin binding. Therefore, we attempted to isolate the active compounds from 
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the whole C4 by preparative reverse phase high-performance liquid chromatography  
(RP-HPLC). This process yielded two active fractions, that, according to mass 
spectrometry (MS) analysis, corresponded to two specific compouds from the C4 library. 
Morover, one of that compounds was able to displace insulin from IR-A, albeit only 
weakly and at concentration of 0.1 mM, which could indicate that the compound at least 
partially binds to the insulin binding site on IR. 
We can only speculate why the activities of the two compounds isolated by  
RP-HPLC and identified by MS analysis were not manifested as significant activities in the 
deconvoluted libraries. It is possible that the apparent biological activity of the C4 mixture, 
that contained 100 compounds, resulted from a simultaneous additive effect of several 
compounds with weak activities, where the two isolated compounds would probably 
represent the most active of them. We also cannot exclude the possibility that a 
nonidentified active byproduct was present within the original C4 library, which was 
ommited during purification and which was not present in the deconvoluted libraries.  
Nevertheless, despite the unsatisfactory biological results, this study enabled us  
to test our bilogical methodology and to prove its robustness and reliability. It represents a 
unique example of targeting IR with a set of nonpeptide compounds that were specifically 
designed and synthesized for this purpose.  
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5 CONCLUSIONS 
 
Aim 1 
The methodology for testing the ability of the broad spectrum of compounds produced 
in our laboratory to activate IR-A, IR-B and IGF-1R was customized and used for 
testing of several sets of compounds, including: 
 insulin-IGF-1/IGF-2 hybrid analogs containing the A and B chains  
of insulin and the C or D domains derived from IGF-1 or IGF-2 or their 
parts 
 IGF-1 and IGF-2 analogs with mutations in the positions 45, 46 and 49 
(IGF-1) and 45 and 48 (IGF-2) 
 libraries of nonpeptide trifunctional scaffold derived compounds. 
 
Aim 2 
 A set of six new insulin analogs was prepared with the aim to clarify  
the  unexpectedly high ability of [D-HisB24]-insulin to bind and activate IGF-1R. 
 The binding affinities and abilities to activate IR-A, IR-B and IGF-1R of the new 
analogs were determined and an analog ([D-HisB24, GlyB31, TyrB32]-insulin) 
with increased affinities and abilities to activate all the three receptors including 
IGF-1R (12 times increased compared to the [D-HisB24]-insulin and 150 times 
increased compared to insulin) was identified. 
 A methodology for kinetic assays (association and dissociation kinetics, negative 
cooperativity) was customized and used for testing of the kinetic properties  
of insulin, IGF-1 and [D-HisB24, GlyB31, TyrB32]-insulin on IR-A and IGF-1R. 
Different kinetic behaviours were shown to be behind the increased affinity of the 
analog towards IR-A and IGF-1R. 
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